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ABSTRACT 
Caitlin C. Murphy: Examining the increasing incidence of colorectal cancer in younger adults  
(Under the direction of Robert S. Sandler) 
 
The overall incidence of colorectal cancer (CRC) has declined in the U.S., but the 
incidence of CRC in younger adults (age <50) is rapidly increasing. The underlying mechanisms 
that have contributed to this increase are poorly understood. This dissertation project sought to: 
1) describe the demographic, clinicopathologic, and socioeconomic characteristics and 
treatment patterns of younger stages II and II CRC patients; 2) estimate the contribution of age, 
time period, and birth cohort to the increasing incidence of young-onset CRC; and 3) determine 
patterns of colonoscopy use in younger adults.  
Several population-based data sources were leveraged to examine reasons for the 
increasing incidence of young-onset CRC. The National Cancer Institute’s Patterns of Care 
studies were used to describe differences in the characteristics of stages II and III CRC patients 
by age at diagnosis. Hierarchical Poisson models were used to estimate the independent 
contribution of age, time period, and birth cohort on increases in the incidence of young-onset 
CRC. Incidence rates were derived from the Surveillance, Epidemiology, and End Results 
program of cancer registries. The prevalence of CRC risk factors, including obesity, physical 
inactivity, and smoking, were also described across time period and birth cohort using data from 
national surveys. Lastly, MarketScan Commercial Claims and Encounters Data, an employer-
based claims database, was used to characterize patterns of colonoscopy use in younger 
adults.  
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There were differences in the distribution of young-onset CRC by race/ethnicity. A higher 
proportion of black and Hispanic patients were diagnosed at a younger age compared to whites. 
Results of the age-period-cohort analysis showed a significant age and birth cohort effect in 
both younger and older populations, but the effect of time period was only observed among 
older ages. The prevalence of obesity generally increased across both time period and birth 
cohort, while smoking prevalence declined. Trends in physical inactivity remained relatively 
constant. Colonoscopy use among younger adults increased across sex, age, and geographic 
region from 2001 to 2009 and decreased through 2013.  
This study provides strong support for different mechanisms involved in the development 
of CRC across the life course. The factors responsible for increases in young-onset CRC, albeit 
small on in absolute magnitude, remain unknown.  
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CHAPTER 1 
STATEMENT OF SPECIFIC AIMS 
 
The overall incidence and mortality of colorectal cancer (CRC) have declined over the 
past two decades in the U.S., but recent research suggests CRC in younger adults (age <50 
years) is rapidly increasing. Incidence rates have increased annually by up to 4% for rectal 
cancer and 2% for colon cancer among younger patients since the 1970s, with the steepest 
increases in the 40-49 year age group. By 2030, approximately 11% and 23% of all colon and 
rectal cancers, respectively, will be diagnosed in patients younger than the current screening 
age. Because guidelines recommend that screening (with hemoccult testing, colonoscopy, or 
sigmoidoscopy) begin at age 50 for average risk individuals, early recognition of CRC in young 
patients without a known family history or genetic predisposition (i.e., familial adenomatous 
polyposis, Lynch syndrome) is challenging. This is especially concerning because more than 
half of young patients report no family history of CRC, and only a small minority have hereditary 
cancer syndromes.  
Although the magnitude of the increase in young-onset CRC incidence has been 
previously described, the underlying mechanisms that have contributed to this increase are 
poorly understood.  Reasons for the increase in incidence in younger patients remain largely 
unknown. The current literature is limited to single institution settings, small sample sizes, and 
inconsistent inclusion criteria across studies (e.g., age cutoff of young-onset CRC). No study 
has examined the potential influence of modifiable risk factors or health services use on 
changes in incidence. Research is needed to better describe the determinants of CRC in 
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younger adults. This study used a multidimensional approach to address the characteristics of 
and factors contributing to young-onset CRC. The specific aims were as follows: 
Specific Aim 1a: Describe the demographic, clinicopathologic, and socioeconomic 
characteristics of younger and older patients newly diagnosed with stages II and III CRC during 
the period 1990-2010. Hypothesis – Specific Aim 1a: Younger and older stages II and III CRC 
patients differ by demographic, clinicopathologic, and socioeconomic characteristics.   
Specific Aim 1b: Examine differences in treatment patterns, including type of surgery, 
chemotherapy receipt, and radiation receipt, by age at diagnosis. Hypothesis – Specific Aim 1b: 
Younger CRC patients more frequently receive chemotherapy and radiation therapy compared 
to older patients.  
Patients newly diagnosed with stages II and III CRC were identified from the National 
Cancer Institute’s Patterns of Care (POC) studies in 1990-2010. Detailed tumor information 
(e.g., histologic grade, tumor site) was abstracted from patient medical records and verified by 
treating physicians. POC data were linked with the Area Health Resource File to describe 
socioeconomic indicators and healthcare access in this patient population. As a secondary aim, 
treatment patterns (e.g., chemotherapy agents and regimens received) were described. 
Characteristics of younger patients (age <50 years) were compared to older CRC patients (age 
≥50 years) during the same period to determine differences in disease patterns.  
Specific Aim 2a: Estimate the contribution of age, time period, and birth cohort to the 
increasing incidence of young-onset CRC. Hypothesis – Specific Aim 2a: There are differential 
effects of time period and birth cohort in the incidence of CRC by age.  
Specific Aim 2b: Describe changes in the prevalence of lifestyle-related modifiable risk 
factors, including obesity, physical inactivity, and smoking, by time period and birth cohort. 
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Hypothesis – Specific Aim 2b: Changes in the prevalence of modifiable risk factors parallel 
increases in the incidence of young-onset CRC.  
Hierarchical Poisson models were used to determine the extent to which age, time 
period, and birth cohort account for changes in incidence over time. CRC incidence rate data 
was derived from the Surveillance, Epidemiology, and End Results 9 registries (1973-2012). 
Prevalence of obesity (% body mass index ≥30 kg/m2), physical inactivity (% no physical activity 
in last 30 days), and current smoking was estimated using the National Health and Nutrition 
Examination Survey, Behavioral Risk Factor Surveillance System, and National Health Interview 
Survey, respectively.  
Specific Aim 3: Determine patterns of colonoscopy use in individuals younger than age 
50 years. Hypothesis – Specific Aim 3: Colonoscopy use in younger adults has increased over 
time but does not fully account for trends in the incidence of young-onset CRC. 
An estimated 14 million colonoscopies are performed in the U.S. annually, but 
colonoscopy use in younger populations not yet eligible for screening has not been extensively 
studied. Individual-level healthcare claims from MarketScan (Truven Health Analytics, Ann 
Arbor, MI), a large employer-based claims database, were used to determine changes in the 
number of colonoscopies performed in persons age younger than 50 years over the period 
2001-2013. Understanding increases in colonoscopy use provides additional information on 
CRC trends in younger adults that expand knowledge gained in Aims 1 and 2.  
This dissertation study used an innovative approach to leverage data from three large, 
well-defined sources to examine the increasing incidence as a function of patient and tumor 
characteristics, modifiable risk factors (obesity, physical inactivity, current smoking), and health 
services use. By using complementary methods and techniques from the fields of epidemiology, 
demography, and health services, the study provides insight into the reasons for and distribution 
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of CRC in younger populations. Results may inform clinical guidelines and recommendations 
regarding the prevention, diagnosis, and management of CRC in younger adults.   
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CHAPTER 2 
REVIEW OF LITERATURE 
 
A. BACKGROUND 
Increasing Incidence of Colorectal Cancer in Younger Adults 
The incidence of colorectal cancer (CRC) in younger adults is rapidly increasing in the 
U.S.  Data from the National Cancer Institute’s (NCI) Surveillance, Epidemiology, and End 
Results (SEER) Program show the incidence of CRC has increased by up to 5% per year 
among younger patients (age <50 years) since the 1970s.1-6 The steepest increases have 
occurred in the 40-49 year age group. For example, CRC incidence was 11.9 per 100,000 
among 40-44 year olds in 1987 but rose to 17.9 per 100,000 in 2006, an increase of 67%.1 If 
current trends persist, in the next 20 years the incidence of colon and rectal cancer may 
increase by 90% and 124%, respectively, for patients 20-34 years, and by 28% and 46%, 
respectively, for patients 35-49 years (Figure 2.1).7 Despite the overall population trends in 
aging, by 2030, approximately 11% of all colon and 23% of all rectal cancers are expected to be 
diagnosed in patients younger than age 50.7   
The rise of CRC in younger adults (i.e., young-onset CRC) stands in sharp contrast to 
CRC incidence patterns in older populations. Beginning in the 1990s, CRC incidence and 
mortality rates have consistently decreased among adults age 50 years and older, with the 
largest absolute declines among adults 65 years and older.8  Overall 5-year relative survival 
rates have simultaneously increased, from 50% in 1975-1977 to 66% in 2003-2009.8 Much of 
this improvement has been attributed to screening.9 CRC screening facilitates earlier 
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detection of CRC and lowers mortality and incidence by removing premalignant polyps (e.g., 
adenomatous, sessile serrated, traditional serrated). Current guidelines recommend screening 
with colonoscopy, sigmoidoscopy, or fecal occult blood test for those at average risk begin at 
age 50.10 Other than cervical cancer, CRC is the only cancer for which both incidence and 
mortality can be reduced through population-based screening.11  
Challenges of Diagnosing CRC in Younger Adults 
Early recognition of CRC in younger patients is challenging. Because guidelines 
recommend that screening begin at age 50 for individuals at average risk of CRC, it is difficult to 
diagnose CRC in young patients without a known family history or genetic predisposition (i.e., 
familial adenomatous polyposis, Lynch syndrome). This is especially concerning because more 
than half of young patients report no family history of CRC, and a small minority have hereditary 
cancer syndromes.12 A recent study13 found only 5% of individuals in a random sample of 
patients who were diagnosed with CRC before age 50 had Lynch syndrome; this finding is only 
slightly larger than the prevalence of Lynch syndrome (1-3%) in all patients with CRC.14 The use 
of screening in younger populations is limited (i.e., not considered appropriate care), and 
symptoms often go unrecognized. Younger patients who are symptomatic often do not seek 
medical attention for several months after the onset of symptoms, 15,16 and, because CRC is not 
commonly seen in this population, physicians may not attribute symptoms such as abdominal 
pain and rectal bleeding to cancer. 
B. CHARACTERISTICS OF YOUNGER CRC PATIENTS 
Sociodemographic and Clinicopathologic Features of Young-Onset CRC 
Characteristics of younger CRC patients have not been extensively studied. Studies of 
young-onset CRC typically use demographic variables to describe incidence patterns in 
population subgroups (e.g., by race/ethnicity) and clinicopathologic and molecular variables to 
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examine biological features of the tumor that may explain the earlier onset of CRC. Data from 
SEER registries and the National Cancer Database show the incidence of young-onset CRC is 
similar among males and females,2,5,6 but African Americans have higher incidence rates 
compared to non-Hispanic whites.2,5,17 Other factors with the most consistent association with 
young-onset CRC are tumor site (rectum or right-colon),15,18-22 mucinous or signet ring cell 
histology,18,19,21,23-29 poorly differentiated or undifferentiated grade tumors,15,18,21,23,24,26-28,30 and a 
higher stage of disease at diagnosis.15,18,21,23,24,26-28,31,32 Lymphovascular invasion,12,20,21,23-
25,28,33,34 perineural invasion,19,21,23,33,34 and synchronous tumors23,28,33 are less consistently 
associated with young-onset CRC, with some studies reporting a positive relationship and 
others suggesting no association. Tumor growth patterns (e.g., infiltrative vs. expanding, gross 
type) have not been frequently studied.25,28,34 Appendix A provides a summary of the empiric 
findings regarding the relationship between young-onset CRC and select patient and tumor 
characteristics in studies with a comparison group; Appendix B provides a summary of those 
findings in studies without a comparison group.  
Molecular Pathways of CRC Carcinogenesis in Younger Patients 
Established pathways of CRC carcinogenesis only account for a small subset of young 
patients diagnosed with CRC. Carcinogenic pathways are often defined by their molecular 
features: chromosomal instability, microsatellite instability (MSI), and CpG island methylation 
(CIMP), with mutations in specific genes often associated with each pathway.35 The majority of 
CRCs are thought to arise through the classic adenoma-carcinoma sequence of pathogenesis, 
which involves alterations to APC, KRAS, SMAD2, SMAD4, and TP53 genes. APC and KRAS 
mutations are found in 80% and 45% of these carcinomas, respectively.36 The second major 
pathway of carcinogenesis is characterized by the presence of MSI due to defective mismatch 
repair (MMR) genes. In non-inherited CRC, this is almost always due to the acquired promoter 
hypermethylation of the MLH1 gene that silences its expression. Finally, the CIMP pathway is 
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characterized by widespread aberrant DNA hypermethylation at select CpG islands (i.e., DNA 
regions with a high frequency of CpG sites, where a cytosine nucleotide occurs next to a 
guanine nucleotide) and are preferentially located in the proximal colon and associated with 
BRAF mutation.37 Tumors are often both CIMP and MSI-high because methylation-associated 
MSI generally does not occur among sporadic (i.e., not hereditary) cases outside the context of 
CIMP.38 A few investigators have recently explored the molecular features of young-onset CRC 
and found no difference in the overall mutational rate (as measured by the number of single 
nucleotide variations per patients) among younger and older patients.39,40 However, the specific 
mutations involved in young-onset CRC appear to be distinct. SMAD4, MMR genes (MSH6, 
MLH1, MLH2), ARID1A, IGF1R, and KIT have been shown to be more frequently mutated 
among younger patients. Compared to older patients, the majority of tumors from young 
patients do not show KRAS, APC, TP53, and BRAF mutations, 20, 28, 39 which are common 
features of carcinogenic pathways in CRC. These findings suggest the biology of young-onset 
CRC may be different from what is currently known about the biology of CRC in the overall 
population.   
Treatment of Young-Onset CRC  
Younger CRC patients often receive more aggressive treatment regimens. Studies 
consistently show that younger CRC patients more frequently receive chemotherapy and/or 
radiation therapy compared to older patients.19,41 Even among stage II colon cancer patients, for 
whom guidelines recommend against adjuvant chemotherapy,42 a large proportion of younger 
patients receive therapy.33,43-45 The higher proportion of younger CRC patients treated with 
chemotherapy and/or radiation therapy may be an indication of both over-treatment of normal-
risk and appropriate treatment of high-risk (e.g., poorly differentiated histology, lymphovascular 
invasion) patients. Most studies, however, do not describe patterns of care in subgroups of 
patients by age and high-risk features (i.e., do not make the distinction between therapy given 
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because of younger age and therapy given for aggressive tumor biology). Further, differences in 
the type of chemotherapy agents given to older and younger patients have not been well 
studied. Despite more aggressive therapies in younger patients, many studies report that the 
overall survival is no better than that observed in older CRC patients.18,21,23,24,26,33,34,46,47  
The literature on characteristics of younger CRC patients is limited in several ways. Most 
studies are of patients treated in a single institution. Few of the same variables have been 
examined across studies, and even when the same characteristics were studied, they were 
defined or measured differently. Inclusion criteria are not consistent (e.g., some studies define 
young-onset CRC as <40 years while others use <50 years), and there are differences in stage 
at diagnosis among younger and older patients (i.e., younger patients tend to be diagnosed at 
later stages), making comparisons difficult. It is not possible to draw conclusions from the few 
exploratory studies of molecular differences in young- and older-onset CRC. As a consequence, 
we know very little about the relative importance of clinicopathologic and/or molecular features 
in the development of young-onset CRC. Findings of previous studies warrant further 
investigation in larger, population-based samples.  
C. REASONS FOR THE INCREASE IN YOUNG-ONSET CRC 
Modifiable Risk Factors of CRC 
Reasons for the increase in CRC incidence in younger patients are poorly understood. 
Although the magnitude of the increase has been previously described, little is known about the 
underlying mechanisms that have contributed to this increase. Several established modifiable 
risk factors for CRC, including unhealthy diet, obesity, physical inactivity, and smoking, have 
been proposed as the major drivers of the increase in adults age <50 years.48,49 Meta-analyses 
demonstrate significant associations between CRC risk and red and processed meat 
consumption,50,51 adiposity (including measures of body mass index, waist circumference, and 
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waist-to-hip ratio),52-54 sedentary behavior and physical inactivity,55 and cigarette smoking.56 
Although some studies report only a modest association between diet, adiposity, and CRC, the 
relationship between CRC and physical activity is consistent across multiple studies and in 
different settings and populations.57 Increases in the prevalence of many of these risk factors 
have paralleled the rise in young-onset CRC. Consumption of fast food and/or food prepared 
away from home increased 5-fold among children and 3-fold among adults between the late 
1970s and mid-1990s.58 Obesity prevalence has also risen dramatically among adults, from 
13% in 1960-196259 to 35% in 2011-2012.60 Central/abdominal obesity, in particular, which is 
associated with a higher relative risk of CRC54, has increased by nearly 50% in men and women 
over the last 25 years.61 As poor dietary behavior and obesity has risen, physical activity rates in 
children and young adults have also declined. More than half of U.S. adults and adolescents do 
not meet recommended physical activity guidelines.62 The prevalence of current smoking has 
varied over time, with an overall decreasing trend; however, younger adults (age 18-35) 
reported the highest prevalence of current use of tobacco products in recent national surveys 
compared to other age groups.63 The extent to which changes in the prevalence of risk factors 
explain growth in the incidence of young-onset CRC has not been studied.  
D. ROLE OF HEALTH SERVICES USE 
Prevalence of Endoscopy Use 
Changes in the use of endoscopy procedures, such as colonoscopy, may also facilitate 
further understanding of the incidence of CRC in younger patients. Approximately 11-14 million 
colonoscopies are performed each year in the U.S.,64,65 but little is known about the prevalence 
of colonoscopy use in populations that are not yet eligible for screening recommendations. 
Across all age groups, the overall use of colonoscopy has dramatically increased in the last 15 
years. The National Health Interview Survey, which is considered the gold standard for 
estimating the prevalence of cancer screening behaviors, shows an increase in the use of 
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colonoscopy for CRC screening, from 19% in 2000 to 55% in 2010.66,67 Other studies of 
administrative billing claims estimate there were 3,800 lower endoscopies (for any indication) 
performed per 100,000 insurance enrollees in 2009, an increase of 17% since 2000.65   
Colonoscopy is a key component of the CRC care continuum. Although adults age <50 
years generally do not undergo routine colonoscopy, patterns of colonoscopy use in younger 
populations may explain some of the increase in young-onset CRC. For example, if 
colonoscopy use has increased by 10%, while the incidence of CRC has simultaneously 
doubled, it would suggest that endoscopy does not fully account for the increase in young-onset 
CRC. Understanding the use of colonoscopy in persons age <50 years is important in 
determining the extent to which endoscopy independently accounts for changes in the incidence 
of young-onset CRC.  
E. SUMMARY 
Multidimensional Framework 
The burden of young-onset CRC is rapidly increasing. Reasons for this increase are 
complex. Most studies have failed to consider the multiple influences that have likely contributed 
to CRC in younger adults, instead only focusing on a single dimension (e.g., clinicopathologic 
characteristics) of CRC. Evidence is lacking regarding the impact of modifiable risk factors and 
health services use on young-onset CRC. Guided by a conceptual model (Figure 2.2), this 
dissertation project used complementary methods to better describe and understand the 
underlying mechanisms that have led to the increase of CRC in adults age <50 years. 
Innovation of the Study 
This study was the first to examine reasons for the increase in young-onset CRC. The 
rapid growth in CRC among younger adults has been well described, but several important gaps 
in understanding remain. Sociodemographic characteristics and clinicopathologic features of 
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young CRC patients are largely unknown. Many studies are limited by small sample sizes, 
confounding by stage at diagnosis, single institution settings, and lack of a comparison group. In 
addition, the etiology of young CRC is not well understood. Trends in unhealthy dietary choices, 
obesity, and physical inactivity, and endoscopy use among younger adults may contribute to 
increases in CRC. However, risk factors have not been systematically evaluated in this setting, 
and no study has examined patterns of colonoscopy use in younger adults not eligible for 
screening recommendations. Population-based analyses are critical to understanding the 
unique disease patterns of young-onset CRC. This dissertation project used an innovative 
approach to address these concerns by leveraging data from three large, well-defined sources 
(majority population-based) to examine the increasing incidence of young-onset CRC as a 
function of patient and tumor characteristics, lifestyle-related modifiable risk factors (obesity, 
physical inactivity, current smoking), and health services use. By using complementary methods 
and techniques from the fields of epidemiology, demography, and health services, the study 
provides insight into the reasons for and distribution of CRC in younger populations. Results can 
be used to inform clinical guidelines and recommendations regarding the prevention, diagnosis, 
and management of CRC in younger adults.  
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Figure 2.1. Annual percentage change-based predicted incidence rates of colon (A) and rectal 
(B) cancers by age compared with incidence rates in 201068  
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Figure 2.2. Conceptual model of increasing incidence of young-onset colorectal cancer
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CHAPTER 3 
METHODS 
 
The overall goal of this dissertation study was to determine the underlying mechanisms 
that have contributed to the rising incidence of young-onset colorectal cancer (CRC). Three 
cohorts were assembled from large, well-defined data sources to gain insight into the reasons 
for and distribution of CRC in younger populations (Table 3.1).  
A. SPECIFIC AIM 1 APPROACH 
Study Design 
In Specific Aim 1, we described the sociodemographic characteristics and 
clinicopathologic features of younger (age <50 years) patients diagnosed with CRC.  As a 
secondary aim, we described treatment patterns (e.g., type of surgery and receipt of 
chemotherapy and radiation therapy) in this population. Stages II and III CRC patients were 
sampled from the National Cancer Institute’s Surveillance, Epidemiology, and End Results 
(SEER) program of cancer registries. SEER routinely collects information from hospitals, 
pathology laboratories, surgical centers, and radiation facilities on patient demographics, tumor 
characteristics, and first-course treatment for all persons diagnosed with cancer residing in 
SEER geographic regions. Chemotherapy and radiation therapy (neoadjuvant and adjuvant) are 
often underreported in SEER; therefore, the NCI annually conducts Patterns of Care (POC) 
studies on a sample of patients with select cancers to assess the extent to which adjuvant 
therapies are received in clinical practice.  
Patients’ medical records were abstracted to verify information on patient demographics 
(age, sex, race/ethnicity), clinicopathologic characteristics (tumor site, stage, histologic grade, 
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KRAS mutation, BRAF mutation, microsatellite instability [MSI]) and treatment planned or given 
as reported in SEER. As part of POC studies, additional treatment detail, including receipt of 
specific chemotherapy agents, radiation therapy, and dates of treatment following diagnosis, 
was collected from medical records by trained abstractors. Because adjuvant therapies are 
often given outside of the hospital setting, and SEER data are primarily hospital-based, the 
treating physician was contacted to verify therapy received or recommended. Treating 
physicians were also asked to provide names and addresses of other physicians who may have 
treated the patients, who were subsequently contacted for treatment information. Doctor 
verification substantially improves completeness of chemotherapy ascertainment or confirms 
that no chemotherapy or radiation were given. Physician responses were received on more than 
85% of sampled patients.  
We linked POC data with the Area Health Resource File (AHRF), an extensive county-
level database comprised of socioeconomic indicators (e.g., education level, % living below 
poverty line). Linking AHRF with POC by patient county of residence allowed us to better 
describe sociodemographic characteristics of the cohort. A cohort design based on extant data 
was an efficient approach to obtain a large sample of CRC patients and address our research 
question. Such designs are often called historical because all follow-up information is available 
at the study outset; however, all data within POC were collected prospectively (i.e., in the year 
following diagnosis), and we did not take any future events into consideration when creating the 
cohort.   
Study Population 
Stages II and III CRC patients in participating SEER registries were eligible for POC 
studies in 1990, 1991, 1995, 2000, 2005, and 2010.41,69,70 Participating registries included the 
metropolitan areas of Atlanta (1990-2010), Detroit (1990-2010), Los Angeles (1995, 2000, 2005, 
2010), San Francisco (1990-2010), San Jose-Monterey (2000, 2005, 2010), and Seattle (1990-
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2010), and the states of Hawaii (1990-2010), New Mexico (1990-2010), Iowa (1990-2010), 
Connecticut (1990-2010), Alaska (2000 only), Utah (1990-2010), Kentucky (2010 only), Greater 
California (2005, 2010), Louisiana (2005, 2010), and New Jersey (2005, 2010). Eligible patients 
were stratified within registries by tumor site (colon or rectum), and a random sample was taken 
from within each stratum. Beginning in 1995, there was oversampling by race/ethnicity to obtain 
more stable estimates for racial subgroup analyses. Patients were sampled according to the 
staging scheme used by SEER in each study year. In 1990, 1991, 1995, and 2000, patients 
were sampled based on Extent of Disease (EOD) 10 coding, and in 2005 and 2010, patients 
were sampled based on Collaborative Staging (CS) coding. EOD and CS coding record the 
farthest extent of disease based on the combined clinical and pathological assessment. Clinical 
information took priority when a patient was treated with preoperative therapy, otherwise 
pathological information took priority. TNM staging was derived by mapping T and N status from 
EOD and CS coding. Stage II included T3 or T4 tumors with no positive regional lymph nodes, 
and stage III included any T1 to T4 tumors with regional lymph node involvement. These stage 
definitions also correspond approximately to stage B2 and C of the Aster-Coller modification of 
Duke’s original staging system.  
Patients were ineligible for POC studies if they were younger than age 20; previously 
diagnosed with cancer (excluding non-melanoma skin cancer); diagnosed at autopsy or on 
death certificate only; or diagnosed with a synchronous cancer. We considered young CRC 
patients to be those age 20-49 years, and older CRC patients were age greater than 50 years.  
An estimated 7,000 patients were diagnosed with stages II and III CRC during the study 
period; approximately 1,400 of these were patients age <50 years (Table 3.1). POC studies 
provided a number of unique advantages for conducting population-based epidemiologic 
research because each participating registry area has a defined population, and detailed tumor 
and treatment information was abstracted from patient medical records and verified by treating 
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physicians. The data available in POC studies provided a greater breadth and depth of 
information than that available solely from medical claims and/or SEER registries. The age and 
sex distributions of patients in POC reflect those of the U.S. population, and the SEER program 
includes registries with a high percentage of African Americans (Detroit, Atlanta, Louisiana), 
Asian Americans (Seattle, San Francisco, Los Angeles, San Jose-Monterey), and Hispanics 
(Los Angeles, Greater California). The large size and ethnic diversity of this study population 
were strengths that enabled us to examine CRC characteristics within population subgroups by 
race and sex.  
Covariate Assessment 
A summary of covariates that were measured in Specific Aim 1 is provided in Table 3.2. 
Demographic and clinicopathologic information was abstracted from patient medical records by 
trained abstractors. An example of the abstraction form is shown in Appendix C. Demographic 
characteristics included age (years), sex (male, female), race/ethnicity (non-Hispanic white, 
non-Hispanic black, Hispanic, other), insurance (private, Medicare, Medicaid, other, none), and 
delivery site/geographic region. Clinicopathologic characteristics included tumor site (ascending, 
transverse, or descending colon, hepatic flexure, splenic flexure, sigmoid colon, rectosigmoid 
junction, rectum), stage (II, III), histology (adenocarcinoma, mucinous, signet ring cell), and 
histologic grade (well, moderately, poorly, undifferentiated).  
TNM staging was derived by mapping T and N status from EOS and CS coding 
(described above), where stage II included T3 or T4 tumors with no positive regional lymph 
nodes, and stage III included any T1 to T4 tumors with regional lymph node involvement. Low-
grade CRC was defined as well and moderately differentiated tumors, and high-grade CRC 
included poorly differentiated and undifferentiated tumors, according to established protocols of 
the College of American Pathologists and American Joint Committee on Cancer.71,72 Mucinous 
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and signet ring cell tumors were defined as those with more than half of the tumor displayed as 
extracellular mucin or signet rings, respectively.73,74 
KRAS mutation, BRAF mutation, and MSI were collected in 2010 only. The purpose of 
KRAS testing is to identify point mutations in codon 12 and 13 of the KRAS gene. There are 
currently no specific methodology recommendations and no FDA-approved KRAS mutation 
tests available; however, all methods are based on the polymerase chain reaction (PCR). The 
most common method for KRAS testing is direct sequencing of KRAS PCR products.75 Although 
the specific method of KRAS genotyping may differ across POC sites, a recent study reported 
good agreement (90% concordance) in KRAS mutation status of tumors from patients across 
different detection methods (e.g.., sequencing, hybridization).76 BRAF mutation testing, used to 
detect the presence of a V600E mutation on the BRAF gene, is most often performed by 
amplification and direct DNA sequence analysis, although allele-specific PCR is an acceptable 
alternative method. PCR-based BRAF testing requires small quantities of DNA and is highly 
sensitive.77 Finally, microsatellite status is evaluated using tissue sections from the primary 
tumor with a PCR assay using a panel of five microsatellite markers (BAR-25, BAT-26, D2S123, 
D5S346, D17S250), as recommended by the NCI.78 Tumors were considered MSI-high if two or 
more of the five microsatellite sequences were mutated; tumors with only one mutated 
sequence were classified as MSI-low. Microsatellite stable tumors had no mutations in the 
microsatellite panel.  
Any surgery, radiation therapy, and chemotherapy given as first-course treatment was 
abstracted from patient medical records. An example of the treatment verification form is given 
in Appendix D. Surgery included surgery type (polypectomy, partial colectomy, subtotal 
colectomy/hemicolectomy, total colectomy, total proctocolectomy, or coloproctotectomy with 
resection of a continuous organ), date, number of lymph nodes examined, number of positive 
lymph nodes, pathological margins, and whether the colectomy was a laparoscopic procedure. 
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Radiation therapy included date of initiation, sequence with surgery (before, after, before and 
after, intraoperative), and sequence with chemotherapy (before, after, concurrent). 
Chemotherapy included dates of initiation (dates reported for all therapies initiated), 
sequence with surgery (before, after, before and after), specific agents (e.g., 5-flourouracil, 
oxaliplatin), and combination regimens (e.g., FOLFOX, FOLFIRI).  
Socioeconomic indicators were derived from POC, SEER, and the AHRF. POC contains 
patient-level information on clinical trial participation, hospital type (private, nonprofit, or 
government), hospital size (based on total bed size), and approved residency training program. 
We also used a composite index of socioeconomic status based on measures developed by 
Yost et al.,79 including occupation, unemployment, poverty, education, income, and housing. 
The index was constructed to assess the relationship between socioeconomic status and 
cancer incidence using SEER data.80 Data used in the index were derived from Census 2000 
and American Community Survey 2005-2009 and reflect the populations and census tracts 
covered by the SEER 17 registries. The index (measured in quintiles) was available for study 
years 2000, 2005, and 2010.  Lastly, we used AHRF measures of per capita income, median 
household income, education level (persons age ≥25 years with less than a high school 
diploma, high school or more, or four or more years of college), poverty (persons living below 
poverty line), unemployment, total number of active physicians, and total number of 
gastroenterologists. All socioeconomic indicators in the AHRF were measured on the county 
level and collected at various time points. In cases where an AHRF variable was not collected in 
the same year as POC, we used the next closest collection year. For example, total number of 
physicians was not collected in AHRF in 2010; therefore, we used data on total number of 
physicians collected in 2008 as a reasonable proxy.    
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Statistical Analysis  
To test the hypothesis that there are differences in the sociodemographic characteristics 
and clinicopathologic features of young-onset CRC and older-onset CRC, we examined the 
distribution of covariates in young (age <50 years) and older (age ≥50 years) CRC patients with 
descriptive statistics (means, medians, minima, maxima, frequencies, cross-tabulations). As 
was appropriate, we also examined the distribution of covariates within subgroups of younger 
and older CRC patients by race and sex. As part of the secondary aim to examine differences in 
treatment patterns, we compared the proportions of younger and older CRC patients who 
received common chemotherapy agents, combination chemotherapy regimens, and radiation 
therapy, as well as differences in type of surgery performed and surgical outcomes (e.g., 
number of lymph nodes examined). For all analyses, proportions and means were calculated 
with stratum-specific sample weights to account for the complex survey design. Sample weights 
were calculated as the inverse of the sampling proportion for each sampling stratum.   
Sensitivity Analysis  
To account for potential heterogeneity of CRC in older patients (e.g., the CpG island 
methylator phenotype is most common in female CRC patients age ≥70 years), we conducted 
sensitivity analyses that further categorized older CRC patients into two age groups: 50-69 
years and ≥70 years. Younger (age <50 years) CRC patients were compared to older CRC 
patients in both the 50-69 and ≥70 year age groups.  
Sample Size and Power  
We assumed that a minimum of 10% absolute difference was meaningful to detect. We 
set the level of significance at 5% and statistical power at 80% for a 2-sided test of all 
hypotheses. Power analyses were conducted in SAS (version 9.3). Table 3.3 provides the 
minimum statistically-detectable group differences across a range of prevalences among older 
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CRC patients (from 10% to 50%). The sample size of 1,400 younger CRC patients and 5,600 
older CRC patients (see Table 3.1) provided 80% power to detect as little as a 4% difference in 
younger and older CRC patients when the prevalence of the covariate was 10% among older 
patients. If the prevalence of a covariate under study was as high as 50% among older patients, 
we were able to detect a difference of 7%.  
B. SPECIFIC AIM 2 APPROACH 
Study Design 
In Specific Aim 2, we estimated the contribution of age, time period, and birth cohort on 
the increasing incidence of young-onset CRC using Poisson cross-classified random effects 
models (CCREM). CCREM have been widely used in sociology and demography research81 
and have more recently been applied to cancer incidence and mortality rates.82 To complement 
incidence data, we also described changes in the prevalence of lifestyle-related modifiable risk 
factors in young-adult (age 21-49 years) populations. We used data from the National Health 
and Nutrition Examination Survey (NHANES), Behavioral Risk Factor Surveillance System 
(BRFSS), and National Health Information Survey (NHIS) to determine the extent to which life-
style related modifiable risk factors (obesity, physical inactivity, and current smoking) have 
paralleled to the increase of young-onset CRC.   
Study Population  
We identified all patients diagnosed with stages I-IV CRC in 1973-2012 from SEER 9 
registries. SEER 9 registries include Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, 
San Francisco—Oakland, Seattle—Puget Sound, and Utah, approximately 9.5% of the U.S. 
population. They are the oldest of the SEER registries, which allowed us to examine incidence 
rates over the longest period of time. Populations covered by SEER are comparable to the 
general U.S. population with regard to race, measures of poverty, and education. We excluded 
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patients with a race/ethnicity other than non-Hispanic white or black from the study population in 
order to obtain more stable estimates for the CCREM approach. There were 378,000 patients 
diagnosed with stages I-IV CRC in the SEER 9 registries from 1973-2012, of which we 
anticipated 30,000 cases would be among those age 21-49 years (Table 3.1). We derived 
obesity prevalence from NHANES phases I (1971-1975), II (1976-1980), and III (1988-1994) 
and the continuous cycles (1999-2012); physical inactivity prevalence from BRFSS in 1984-
2010; and the prevalence of current smoking from NHIS in 1974, 1976-1980, 1983, 1985, 1987-
1988, 1990-1995, and 1997-2012 (Table 1). NHANES contains anthropometric measures of 
height and weight from population-based samples of U.S. adults. BRFSS annually collects data 
in all 50 states via telephone surveys regarding health-related risk behaviors, chronic health 
conditions, and the use of preventive services. Widely considered the gold standard in tracking 
health status, the NHIS collects data on a broad range of health topics through personal 
household interviews. Obesity, physical inactivity, and current smoking were calculated specific 
to four race-sex subgroups (white males, white females, black males, black females), ages 21-
49 years, using survey data.  
Covariate Assessment  
SEER defines CRC anatomically as being located in the colon (ascending, transverse, 
descending, hepatic flexure, splenic flexure, sigmoid colon; International Classification of 
Disease for Oncology, Third Edition [ICD-O-3] codes 18.2-18.9) or rectum (rectum, rectosigmoid 
junction; ICD-O-3 codes 19.9, 20.9). For the purposes of this study, we considered 
adenocarcinoma histology (morphology codes 814_3, 84803, 84903, 82103, 82203, 82613), 
which represents more than 98% of all CRCs. SEER program registries routinely collect data on 
patient demographics, primary tumor site, tumor morphology and stage at diagnosis, and the 
NCI guides all registries to achieve data content and compatibility acceptable for pooling data. 
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The SEER Program is viewed as the standard for quality among cancer registries with > 98% 
case ascertainment.  
Obesity 
The prevalence of obesity was derived from NHANES phases I (1971-1975), II (1976-
1980), and III (1988-1994) and the continuous cycles (1999-2012). NHANES is the only study 
that provides estimates on anthropometric measures for the U.S. population and has been used 
by many researchers for more than 30 years. Data collection for NHANES consists of an initial 
household interview, an in-home personal interview, and a standardized physical examination in 
a specially equipped mobile examination center. The exam includes physical measurements, a 
dental examination, and the collection of blood and urine samples for laboratory testing. All 
NHANES participants are eligible for the body measures components of the exam. The 
complete set of measurements includes weight, height, upper leg and arm length, mid-arm and 
waist circumferences, and triceps and subscapular skinfolds. Obesity is measured as body 
mass index (BMI) ≥ 30 kg/ m2. A trained health technologist and recorder work together to 
collect the anthropometry data. Examinations are conducted in mobile exam centers, which 
helps to standardize their administration. All data collection procedures are overseen by the 
Centers for Disease Control and Prevention (CDC).  
Physical Inactivity 
Physical inactivity prevalence was derived from BRFSS survey data from years 1984-
2010. Survey data are publicly available and have been reported in numerous publications. 
Assessing physical activity over time is difficult because guideline-based recommendations 
have changed in the U.S. Prior to 1985, recommendations called for vigorous intensity exercise 
for at least 3 times/week for at least 20 minutes.83 A new recommendation84 was issued in 1995 
by the CDC and American College of Sports Medicine that allowed for 30 minutes of moderate 
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intensity physical activity, which could be accumulated over the course of the day, almost daily. 
The recommendation was meant to provide a choice for less intense kinds of activities, and it 
heightened awareness of what could be considered physical activity (e.g., gardening, yardwork). 
Although our understanding of vigorous activity has changed over time, the definition of physical 
inactivity has remained relatively constant. BRFSS provides a consistent measure of physical 
inactivity across all survey years, defined as no leisure-time activity or exercise in the last 30 
days. Data from BRFSS are preferable to other national surveys (e.g., NHIS), where physical 
activity and exercise have been assessed with a variety of questions and in different survey 
years, precluding meaningful comparisons over time. BRFSS data collection procedures are 
overseen by the CDC. Surveys are administrated continuously through the year by state health 
departments via random digit dialing. Starting in 2011, BRFSS changed weighting methodology 
and included cell phone only respondents in the sampling frame; data from 2011 forward are not 
directly comparable to previous years of BRFSS data. Therefore, we used 2010 data as the 
estimate for the prevalence of physical activity during the corresponding 2010-2012 period. 
Current Smoking 
We obtained the prevalence of current smoking from the NHIS in years 1974, 1976-
1980, 1983, 1985, 1987-1988, 1990-1995, and 1997-2012. NHIS is regarded as the primary 
data source for tracking progress toward achieving national health objectives. Adult tobacco use 
was first measured on the NHIS as part of the 1965 smoking supplement and has been included 
annually in the adult health behaviors section of NHIS since 1997. The basic NHIS cigarette 
smoking questions consist of a screener question, “Have you ever smoked at least 100 
cigarettes in your entire life?” and follow-up questions about current smoking practices. 
Although follow-up questions have varied slightly across survey years (e.g., from “Do you 
smoke now?” to “Do you smoke every day, some days, or not at all?”), the same smoking status 
variable recodes are included in the public use data files. Participants are categorized as current 
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(including both every day smoker and some day smoker), former, or never smokers. NHIS data 
are collected through personal household interviews conducted by interviewers employed and 
trained by the U.S. Census Bureau.  The CDC oversees all data collection procedures.  
Statistical Analysis  
We specified Poisson CCREM using multilevel data described above. CCREM are a 
type of hierarchical age-period-cohort (HAPC) models that estimate independent age effects 
(i.e., distribution of the outcome across the life course due to aging), period effects (i.e., secular 
trends in the prevalence of an outcome that occur in all ages), and cohort effects (i.e., variation 
in the outcome among those born in or around the same year). HAPC models avoid the 
identification problem85 of linear APC regression models (i.e., age, period, and cohort are 
perfectly collinear) because the three effects (age, period, cohort) are not assumed to be linear 
and additive at the same level of analysis.86,87 By pooling SEER incidence data, we created a 
rectangular age by period array where columns correspond to age-specific incidence rates in 
each period, and rows are age-specific incidence rates across all periods (Figure 3.1). Linking 
the diagonal cells of the array gives incidence rates that belong to individuals born in the same 
calendar year and age together (i.e., birth cohort). Although only a longitudinal panel study 
design provides data from true birth cohorts that follow identical individuals over time, this 
design allowed for a synthetic cohort approach, used often in demography research.85 The 
synthetic cohort approach has the advantage of simultaneously testing age and period effects 
because it is based on nationally representative data (e.g., SEER) collected regularly from one 
period to the next and covers several decades.   
HAPC-CCREM is a member of the class of linear mixed models, and is the most widely 
used form of hierarchical or multivariable linear models.88 Linear mixed models consist of two 
components: the level 1 component is a regression of an individual-level outcome variable on a 
set of individual level covariates (i.e., age) with an intercept term, fixed regression slope 
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coefficients, and an individual-level random error term. The level 2 component uses level 1 
regression coefficients as outcomes and contains intercepts and specification of random effect 
coefficients for the effects of each cohort and time period distinguished in the model.81 
Level 1 component: log(yijk) = β0jk + β1AGEijk + β2AGE2ijk + β3SEXijk + β4RACEijk + eijk 
  with eijk ~ N (0, σ2) 
Level 2 component: β0jk = ϒ0 + c0j + p0k  
  with c0j ~ N (0, Τc), p0k ~ N (0, Τk) 
Combined model: log(yijk) = ϒ0 + β1AGEijk + β2AGE2ijk + β3SEXijk + β4RACEijk + c0j + p0k + eijk 
where: i = 1,2,…,njk incidence rates within cohort j and period k; 
            j = 1,…,13 birth cohorts; 
            k = 1,…,9 time periods 
The combined model is defined by the statistical parameters: the regression coefficients, 
ϒ0, β1, β2, β3, and β4, and the variance components, σ2, Τc, and Τk. Regression coefficients are 
interpreted similarly as in Poisson regression, where a one unit change in the predictor variable 
corresponds to the expected change in the difference in the logs of expected counts by the 
respective regression coefficient, given all other variables in the model are held constant. 
Variance components are interpreted as the period or cohort effect, or the contribution of cohort 
j and period k averaged over all periods and cohorts, respectively. We used restricted maximum 
likelihood (REML) to estimate parameters. REML is preferable to other methods (e.g., maximum 
likelihood (ML)), particularly for estimating variance, because it takes into account the loss of 
degrees of freedom that result from first estimating regression parameters. ML estimators for 
variance components have a downward bias, but REML estimators do not.   
To test the hypothesis that lifestyle-related modifiable risk factors have paralleled the 
increasing incidence of young-onset CRC, we pooled period-obesity, -physical inactivity, and –
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current smoking prevalence across all ages for four sex-race groups (white males, white 
females, black males, black females) for corresponding NHANES, BRFSS, and NHIS periods of 
data collection, respectively. Prevalence by cohort was derived by averaging age-specific 
prevalence for the same four sex-race groups across the relevant time periods. Because no 
NHANES data were available in certain years, we interpolated obesity prevalence by averaging 
the prevalence for the previous and subsequent periods and/or cohorts. Physical activity was 
not measured in BRFSS prior to 1984; therefore, the analysis of physical inactivity was limited to 
years 1984-2012. This approach allowed us to quantify the extent to which these modifiable risk 
factors parallel the increasing incidence of young-onset CRC.  
Sensitivity Analysis  
To account for the possibility that incidence of young-onset CRC increases linearly with 
BMI (vs. threshold effect of BMI ≥30), we also calculated period- and cohort-specific mean and 
median BMI.  
Sample Size and Power 
The primary purpose of Specific Aim 2 was to determine the contribution of age, time 
period, and birth cohort on the increasing incidence of young-onset CRC using CCREM 
specification of HAPC models. CCREM have only recently emerged as a type of APC analysis, 
and there is no established or formal method for calculating statistical power. However, the 
CCREM approach is an improvement over linear APC models because it allows researchers to 
identify key explanatory factors in addition to age, period, and cohort indicators. We estimated 
there would be 378,000 total patients diagnosed with stages I-IV CRC in SEER 9 registries from 
1973-2012, with approximately 30,000 cases in patients age <50 years (Table 3.1). Therefore, 
we felt the sample size was sufficiently large to detect meaningful associations.   
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C. SPECIFIC AIM 3 APPROACH 
Study Design 
In Specific Aim 3, we characterized the patterns of colonoscopy use in younger adults by 
analyzing administrative claims of employer-insured adults in the MarketScan Commercial 
Claims and Encounters data (MarketScan; Truven Health Analytics, Ann Arbor, MI). Using a 
cohort design based on extant data allowed us to efficiently obtain a large sample size and 
address our research question. Because current guidelines do not recommend routine 
colonoscopy for individuals age <50 years, the prevalence of colonoscopy use in a younger 
population was likely to be low (~5%). A claims-based analysis yielded a large enough cohort to 
determine use of a relatively uncommon procedure. Further, colonoscopy is accurately reported 
in claims data because it is an expensive procedure. Although follow-up information was 
available at the study outset, MarketScan collected all claims prospectively 
Study Population  
The study population was derived from individuals with health care claims in 
MarketScan, a large employer-based claims database. MarketScan contains more than 500 
million claim records on person-specific clinical utilization, expenditures, and enrollment across 
inpatient and outpatient services from approximately 100 payors (Table 3.1). We identified 
individuals aged 18-49 years during the period 2001-2013 (i.e., the most recent release of 
MarketScan data) using electronic administrative records.  There is no diagnosis code or 
administrative algorithm to determine the presence of inherited cancer syndromes (e.g., Lynch 
syndrome). As a result, we could not reasonably exclude younger adults who are recommended 
to undergo colonoscopy (i.e., those at higher risk or with a family history), but we anticipated the 
proportion of these patients to be minimal and constant across study years.13,14 Patients 
represented in MarketScan data are all insured through their employers; therefore, findings 
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cannot be generalized to uninsured patients or those without access to endoscopy services. 
However, MarketScan is preferred to other claims data because data are fully integrated 
(inpatient, outpatient, enrollment) at the patient-level, represent all ages (i.e., compared to 
Medicare claims which only cover age ≥ 65), and are not limited to a single payer or geographic 
region. 
Covariate Assessment  
Any colonoscopy delivered in the outpatient setting was identified from administrative 
claims in the outpatient services table in MarketScan. Colonoscopy use was identified with 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
procedure codes and Common Procedural Terminology (CPT) codes. Several validation studies 
of administrative claims data support the use ICD-9-CM and CPT codes for estimating 
colonoscopy utilization, with specificity of 72-76% and sensitivity of 70-83%. Higher sensitivity is 
considered the most important measure of validity when describing ascertainment of a 
procedure in administrative data.89  El-Serag and colleagues90 developed an algorithm and 
applied it to several decades of national Veterans Health Administration (VHA) administrative 
data to evaluate trends in colonoscopy utilization, which is widely used in health services 
research of endoscopy procedures. The algorithm was later modified to include parameters 
(e.g., other administrative data such as ICD-9 diagnosis codes) to determine why a colonoscopy 
was performed, with 83% sensitivity and 76% specificity for colonoscopy indication.91 ICD-9-CM 
and CPT codes used to identify colonoscopy are listed in Table 3.4. 
Statistical Analysis  
To test the hypothesis that colonoscopy use has increased over time, we estimated the 
rate of colonoscopy in each calendar year (2001-2013). We summed the total number of 
months that individuals aged 18-49 years were enrolled in their insurance plan. For example, 
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patients who were enrolled in their insurance plan for 8 months in the year 2001 (January 1, 
2001 to December 31, 2001) contributed 8 months of “enrollee-time” during that year. Patient 
enrollee-time was counted in each calendar year without regard to enrollment in previous or 
subsequent years (i.e., patients could contribute enrollee-time across all calendar years.) Using 
standardized denominators of enrollee-time is a reasonable approach because our primary goal 
was to estimate change in colonoscopy use by year. 
We also examined differences in the rate of colonoscopy use (overall and in calendar 
study year) by sex (male, female), age (18-29 years, 30-39 years, 40-49 years), and geographic 
region (northeast, north central, west, south). We did not examine the indication for colonoscopy 
because our primary interest was in understanding CRC incidence trends (i.e., a colonoscopy 
would detect cancer regardless of why it was performed).   
Sample Size and Power  
The primary purpose of Specific Aim 3 was to determine increases in the use of 
colonoscopy across study years (2001-2013). Given the expected low prevalence of 
colonoscopy in patients age <50 years, we assumed that a minimum of 1% absolute difference 
per year was meaningful to detect. We set the level of significance at 5% for a 2-sided test of all 
hypotheses. The estimated sample size of 7,000,000 continuously-enrolled adults ages 18-49 
years (see Table 3.1) provided >99% power to detect a1% increase in colonoscopy use per 
year. 
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Table 3.1: Data source, description, and preliminary data by study aim 
    
Aim Data Source, years Description Preliminary Data 
Aim 1 
Patterns of Care (POC), 
1990-2010 
Detailed tumor and 
treatment information from 
a random sample of 
patients residing in SEER 
registry areas 
7,000 total patients 
diagnosed with stages II-
III CRC; approx. 1,400 
cases among patients 
<50 years 
Aim 2 
SEER 9, 1973-2012 
Cancer incidence and 
survival from regional 
registries; routinely collects 
data on patient 
demographics, primary 
tumor, and tumor type and 
stage 
378,000 total patients 
with stages I-IV CRC; 
approx. 30,000 cases 
among patients <50 
years 
NHANES, phases I (1971-
1975), II (1976-1980), and 
III (1988-1994) and 
continuous cycles (1999-
2012) 
Anthropometric measures 
of height and weight from 
population-based samples 
of adults  
Approx. 5,000 survey 
participants in each year 
BRFSS, 1984-2010 
Responses to telephone 
survey questions on recent 
physical activity and 
exercise from population-
based samples of adults 
Approx. 100,000 survey 
participants in each year 
NHIS, 1974, 1976-1980, 
1983, 1985, 1987-1988, 
1990-1995, 1997-2012 
Responses to personal 
household interview 
questions on current 
smoking habits from 
population-based samples 
of adults 
Approx. 87,500 survey 
participants in each year 
Aim 3 
MarketScan Commercial 
Claims and Encounters 
(Truven Health Analytics), 
2001-2013 
Large employer-based 
commercial claims 
database from approx. 100 
payers 
Approx. 7 million 
continuously-enrolled 
adults age 18-49 years in 
each year 
Abbreviations: SEER: Surveillance, Epidemiology, and End Results; NHANES, National Health and 
Nutrition Examination Survey; BRFSS, Behavioral Risk Factor Surveillance System; NHIS, National 
Health Interview Survey 
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Abbreviations: SEER, Surveillance, Epidemiology, and End Results; MSI, microsatellite instability; POC, 
Patterns of Care; AHRF, Area Health Resource File 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2: Summary of covariates measured in Specific Aim 1 
 
Type Covariates Source Time Measured 
Demographic 
Age, sex, race/ethnicity, 
insurance, geographic region 
SEER Diagnosis 
Clinicopathologic 
Tumor site, stage, histology, 
grade, BRAF mutation, KRAS 
mutation, MSI 
POC; patient 
medical record 
Cancer-directed 
surgery 
Treatment 
Surgery type and pathology, 
radiation therapy, chemotherapy 
agents and regimens 
POC; patient 
medical record 
4 months post-
treatment 
Socioeconomic 
indicators 
Hospital type, hospital size, 
teaching hospital, trial 
participation 
POC 
Cancer-directed 
surgery 
Socioeconomic status composite 
index (measured in quintiles) 
SEER N/A 
Per capita income, median 
household income, education 
level, poverty, unemployment, 
total number of physicians, total 
number of gastroenterologists 
AHRF N/A 
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Table 3.3: Minimum statistically-detectable absolute differences in proportions  
 
 Prevalence of Sociodemographic Characteristics and 
Clinicopathologic Features in Older (≥50 years) CRC Patients 
(n=5,600) 
10% 15% 20% 25% 30% 35% 40% 45% 50% 
Minimum Detectable 
Absolute Difference in 
Younger (<50 years) 
Patients (n=1,400) 
4.3% 5.0% 5.5% 6.0% 6.3% 6.5% 6.7% 6.8% 6.8% 
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Table 3.4: ICD-9 diagnosis codes for colonoscopy indication and ICD-9 procedure and CPT 
codes for colonoscopy use 
 
 
ICD-9 Diagnosis Codes 
ICD-9 
Procedure 
Codes 
CPT Codes 
Colonoscopy 
Indication/Use 
7873 (abdominal distention), 7890 
(abdominal pain), 7893 (abdominal 
swelling), 2851, 2859 (anemia), 7830 
(anorexia), 5609 (bowel obstruction), 7879 
(change bowel habits), 5640 (constipation), 
5589, 5645 (diarrhea), 7876 (fecal 
incontinence), 578 (GI bleed), 7921 (heme-
positive stool), 5693 (hemorrhage rectum 
anus), 280 (iron-deficiency anemia), 7870 
(nausea vomiting), 7832 (weight loss), 555 
(Crohn disease), 556 (ulcerative colitis), 
56212 (diverticulitis), 56213 (diverticulosis), 
56985 (angiodysplasia), 5581 (colitis-
radiation), 5600 (intussusception), 5601 
(paralytic ileus), 5647 (megacolon), 5641 
(irritable colon) 
4521, 4522, 
4523, 4524, 
4525, 4542, 
4543, 4823, 
4824, 4836 
44388, 44389, 
44390, 44391, 
44392, 44393, 
44394, 44395, 
44396, 44397, 
45355, 45378, 
45379, 45380, 
45381, 45382, 
45383, 45384, 
45385, 45386, 
45387, 45394, 
45397, 
G0105, 
G0121, 0105, 
0121 
Abbreviations: ICD-9, International Classification of Diseases, Ninth Edition; CPT, Current Procedural 
Terminology  
 
  
 
Figure 3.1: Age-by-time period data structure and synthetic birth cohorts 
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CHAPTER 4 
RESULTS: CLINICOPATHOLOGIC AND SOCIOECONOMIC CHARACTERISTICS OF 
YOUNGER PATIENTS WITH STAGES II AND III COLORECTAL CANCER1 
 
A. INTRODUCTION 
The overall incidence and mortality of colorectal cancer (CRC) have declined over the 
past two decades in the U.S.,8 but recent research suggests the incidence of CRC in younger 
adults (age <50 years) is rapidly increasing. Since the 1970s, incidence rates have increased 
annually by up to 4% for rectal cancer and 2% for colon cancer in younger populations, with the 
steepest increases in the 40-49 year age group.1-6,68 If current trends persist, by 2030, 
approximately 11% and 23% of all colon and rectal cancers, respectively, may be diagnosed in 
patients younger than the current screening age.68 Because guidelines recommend that 
screening (with fecal occult blood testing, colonoscopy, or sigmoidoscopy) begin at age 50 for 
average risk individuals,10 early recognition of CRC at younger ages is challenging unless there 
is a known family history or genetic predisposition (i.e., familial adenomatous polyposis, Lynch 
syndrome). This is especially concerning because more than half of young patients report no 
family history of CRC, and only a small minority have hereditary cancer syndromes.12-14 
As evidence of increases in incidence has mounted, researchers have also become 
interested in CRC in younger adults because some evidence suggests there are differences in 
CRC survival by age. In a pooled analysis of data from clinical trials of metastatic CRC, younger 
                                                          
1 At the time of this writing, the results in this chapter are under review at Cancer Epidemiology. 
Coauthors include Drs. Robert Sandler, John Baron, Jennifer Lund, Hanna Sanoff, and Karyn 
Stittzenberg. 
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(age <50 years) patients had worse progression-free and overall survival compared to patients 
of middle age (approximately age 57 years), despite equivalent cancer stage and treatment.92 
This may suggest younger patients are a higher risk population with more aggressive disease. 
However, mechanisms contributing to reasons for increases in incidence and differential 
mortality rates are poorly understood.  
Little is known about the relative important of sociodemographic and clinicopathologic 
features in the development of young-onset CRC. The literature on characteristics of younger 
CRC patients has been limited in several ways. Most studies are of patients treated in a single 
institution or rely on small sample sizes. Few of the same variables have been examined across 
studies, and even when the same characteristics were studied, they were defined or measured 
differently. Inclusion criteria are not consistent (e.g., some studies define young-onset CRC as 
<40 years while others use <50 years) and differences in stage at diagnosis (i.e., younger 
patients tend to be diagnosed at later stages) make comparisons difficult. As a consequence, 
we know very little about the relative importance of sociodemographic and clinicopathologic 
features in the development of young-onset CRC. Findings from previous research warrant 
further study in large, population-based samples.  
Understanding differences in the characteristics of CRC patients by age may provide 
insight on the underlying factors that have contributed to the growing incidence of CRC in 
younger adults. The purpose of this study was to describe demographic, socioeconomic, and 
clinicopathologic characteristics of younger and older CRC in a population-based sample of 
stages II and III CRC patients. Given the poorer outcomes frequently observed in younger 
patients, we also described the receipt of treatment by age.  
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B. METHODS 
Study Population 
The study population was derived from the National Cancer Institute’s (NCI) Patterns of 
Care (POC) studies. The NCI annually conducts POC studies on a random sample of patients 
with select cancers to complement data routinely collected through the Surveillance, 
Epidemiology, and End Results (SEER) program of cancer registries. Because chemotherapy is 
not reported in SEER, POC studies provide important information on the extent to which 
therapies are delivered in community settings. Stages II and III CRC patients in participating 
SEER registries were eligible for POC studies in 1990, 1991, 1995, 2000, 2005, and 2010.93 
Patients were stratified by registry, sex, age, and race/ethnicity, and a random sample was 
taken from within each strata. There was oversampling by race/ethnicity in 1995, 2000, 2005, 
and 2010 to obtain more stable estimates. Patients were ineligible for POC studies if they were 
younger than age 20, previously diagnosed with cancer (excluding non-melanoma skin cancer), 
diagnosed at autopsy or on death certificate only, or diagnosed with a synchronous cancer. For 
purposes of this analysis, we further excluded patients with tumors in the appendix (n=4), who 
did not undergo cancer-directed surgery (n=171), or with incomplete information to determine 
TNM staging (n=18).  
Covariates 
We examined the demographic, clinicopathologic, and socioeconomic characteristics of 
younger (age <50 years) and older (age 50-64 years, age ≥70 years) CRC patients. We also 
described treatment patterns (e.g., receipt of chemotherapy) in the study population.  
 Patient demographics included age (<50, 50-69, ≥70 years), sex, race/ethnicity (non-
Hispanic white, non-Hispanic black, Hispanic, other), and insurance (private, Medicare only, any 
Medicaid, none).  
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Clinicopathologic features included tumor site (right, left, and sigmoid colon, rectum), 
stage at diagnosis, histologic grade (well/moderately differentiated, poorly/undifferentiated), 
mucinous or signet ring cell histology, and receipt of microsatellite instability (MSI) testing. 
Tumor site included right colon (cecum, ascending colon, hepatic flexure, transverse colon), left 
colon (splenic flexure, descending colon), sigmoid colon, and rectum (rectosigmoid junction, 
rectum) according to the International Classification of Disease for Oncology, 3rd edition (ICD-O-
3). Data on MSI were collected in 2010 only.  
Socioeconomic indicators were derived from POC, SEER, and the Area Health 
Resource File (AHRF). POC contains patient-level data on hospital type (private, government, 
nonprofit), an approved residency training program, total bed size, and cancer clinical trial 
enrollment. We also used a composite census-tract index of socioeconomic status based on 
measures developed by Yost et al.,79 including occupation, unemployment, poverty, education, 
income, and housing. The index was constructed to assess the relationship between 
socioeconomic status and cancer incidence using SEER data, as described elsewhere.80 Data 
used in the index were derived from Census 2000 and American Community Survey 2005-2009 
and reflect the populations and census tracts covered by the SEER 17 registries. The index 
(measured in quintiles) was available for study years 2000, 2005, and 2010.  In addition, study 
data were linked with the AHRF, an extensive county-level database of socioeconomic 
indicators maintained by the U.S. Department of Health and Human Services. We used AHRF 
data on per capita income, median household income, education level (% of persons age ≥25 
years with less than a high school diploma, high school or more, or four or more years of 
college), poverty (% of persons living below poverty line), unemployment (unemployment rate), 
total number of active physicians, and total number of gastroenterologists. Cutpoints for all 
AHRF variables were based on approximate tertiles. Income measures were adjusted to 2010 
dollars.  
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Treatment patterns included type of surgery (partial, subtotal, total colectomy), 
laparoscopic surgery, number of lymph nodes examined (0, 1-11, ≥12), positive margins, receipt 
of chemotherapy, and receipt of radiation therapy (among rectal cancer patients only). As part of 
POC studies, treatment information was abstracted from medical records and verified by 
treating physicians. Treating physicians were also asked to provide names and addresses of 
other physicians who may have treated the patient, who are then contacted for additional 
treatment details. Doctor verification substantially improves completeness of treatment 
ascertainment. 
Statistical Analysis 
Descriptive statistics (e.g., proportions, means) were used to examine the distribution of 
covariates by age at diagnosis (<50 years, 50-69 years, ≥70 years). To account for potential 
differences by race/ethnicity, we conducted a stratified analysis of select covariates in the 
subgroup of younger (age <50 years) non-Hispanic white (n=317), non-Hispanic black (n=200), 
and Hispanic (n=189) patients. We also examined the proportion of patients who received 
chemotherapy and radiation therapy by tumor site (colon vs. rectum), stage at diagnosis, and 
age. Patients who received therapy or were recommended but it was unknown whether they 
received therapy were considered to have received therapy (n=91); patients who refused 
therapy (n=221) were not considered to have received therapy.  
 Sensitivity analyses that considered different categorizations of age at diagnosis (e.g., 
<50 years, 50-64 years, ≥65 years) did not appreciably change the results; therefore, we report 
the results of the primary analysis only.  
 Proportions and means were weighted with stratum-specific sample weights to reflect 
the population (i.e., SEER) from which the sample was drawn. Sample weights were calculated 
as the inverse of the sampling proportion for each sampling stratum.  
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All statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC).  
C. RESULTS  
A total of 6,862 stages II and III CRC patients were included in the analysis. 
Characteristics of the study population by age at diagnosis are shown in Table 4.1. Younger 
patients were more likely to be black (13%) and Hispanic (15%) than patients aged 50-69 years 
(11% and 10%, respectively) and aged ≥70 years (7% for each). More (58%) younger patients 
were diagnosed with stage III (vs. II) CRC. Tumor site varied considerably with age. In younger 
patients, 37% of tumors were located within the rectum and 22% in the right colon, whereas in 
patients over age 70 years, only 18% of tumors were within the rectum 48% were right-sided. A 
similar proportion of patients aged 50-69 years had tumors in the rectum (31%) and right colon 
(32%). The proportion of tumors in the left colon was similar (15%) across all strata of age.   
In the stratified analysis of younger patients by race/ethnicity (Table 4.2), more whites 
had private insurance (86%) compared to both blacks (61%) and Hispanics (68%). There were 
also differences by tumor site. A larger proportion of young white (41%) and Hispanic (33%) 
patients had rectal tumors, whereas tumors in the right colon were the most common in young 
black patients (39%). Although the proportion of tumors classified as high vs. low grade was 
similar by race/ethnicity, a higher proportion of blacks had tumors with mucinous histology 
(18%) compared to whites (10%) and Hispanics (12%).   
Differences in county-level socioeconomic indicators by age at diagnosis are shown in 
Table 4.3. Fewer (15%) young patients lived in areas with lower median household (<$50,000) 
compared to the two older groups of patients (age 50-69 years: 23%; age ≥60 years: 25%). A 
higher proportion of the oldest (age ≥70 years) patients lived in counties with lower poverty 
(<10% living below poverty line), lower unemployment rates (<5%), and higher education. There 
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was no difference in the total number of physicians or gastroenterologists per 100,000 persons 
by age.   
The proportion of patients who received chemotherapy differed by age at diagnosis 
(Table 4.4). Among stage II colon cancer patients, the proportion of patients who received 
chemotherapy decreased with increasing age (age <50 years: 71%; age 50-69 years: 43%; age 
≥70 years: 14%). A larger proportion of stage III colon cancer patients age <50 years (82%) and 
age 50-69 years (82%) received chemotherapy than did patients age ≥70 years (49%). A similar 
pattern was observed in stages II and III rectal cancer, with the vast majority of young patients 
receiving chemotherapy (stage II: 82%; stage III: 94%). The proportion of rectal cancer patients 
who received radiation therapy decreased with increasing age in both stage II (age <50 years: 
72%; age 50-69 years: 61%; age ≥70 years: 43%) and III (age <50 years: 77%; age 50-69 
years: 70%; age ≥70 years: 42%). More young patients received MSI testing (age <50 years: 
28%; age 50-69 years: 10%; age ≥70 years: 7%) and had more lymph nodes (≥12) examined at 
surgery (age <50 years: 72%; age 50-69 years: 60%; age ≥70 years: 53%) (Table 4.1). 
D. DISCUSSION 
In contrast to the decline in CRC incidence in the overall population,8 incidence rates in 
younger populations are rising quickly.1-6,68 Using a population-based sample, we found 
important differences in the distribution of young-onset CRC by race/ethnicity. Younger CRC 
patients were considerably more likely to be black or Hispanic. Consistent with other 
studies,2,5,17,30 we observed a larger proportion of black patients were diagnosed at a younger 
age compared to whites. SEER data from 2012 similarly shows the overall incidence of CRC (in 
all age groups) is higher among blacks (46.8/100,000) than whites (38.1/100,000),94 with a 
disproportionate number of cases diagnosed among younger black patients. 
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We also found a higher proportion of Hispanic patients were diagnosed at younger ages 
than whites. Due to a variety of concerns, including misclassification and cultural or other 
differences among Hispanic and Latino groups, there has historically been limited information 
on cancer trends in Hispanic populations.95 Hispanics represent the fastest-growing and 
youngest minority group in the U.S.,96 and their inclusion in cancer statistics has become 
increasingly relevant. More recent efforts to describe cancer incidence in diverse populations 
show the overall incidence rates of CRC are lower in Hispanics than non-Hispanic whites,97 
although there may be some differences in incidence by country of origin (e.g., higher incidence 
rates are observed in Cuban Americans).98  Another study of young-onset CRC in the California 
Cancer Registry99 found that, although the absolute rate of CRC in all age groups was lowest in 
Hispanics, the largest relative increases in incidence during the study period (1988-2009) were 
for distal colon and rectal cancers among young Hispanic males and females.  
Considerable evidence suggests there are distinct tumor subtypes of CRC,100-102 often 
defined by combinations of deficient DNA mismatch repair or MSI, MLH1 methylation (i.e., CpG 
island methylator phenotype), and mutations in BRAF and KRAS oncogenes. These subtypes 
are also clinically meaningful because of the prognostic and treatment implications (e.g., 
patients with KRAS mutations are unlikely to benefit from anti-EGFR therapies). As our 
understanding of CRC subtypes has improved, an emerging body of literature shows there are 
differences in tumor subtypes across racial groups. For example, in a recent study of BRAF and 
KRAS mutations among patients treated with FOLFOX-based chemotherapy in the Alliance 
N0147 trial,103 KRAS mutation was more common in black patients, while the frequency of 
BRAF mutation was highest in tumors from whites. Other studies104,105 have found that, among 
patients with microsatellite-stable or –low tumors, blacks have a higher frequency of KRAS 
mutations compared to whites. This difference was most pronounced in the proximal colon, with 
no differences in mutation frequency by race in the distal colon or rectum. In our study, right-
 45 
 
sided tumors predominated (39%) in younger black patients, while young white (41%) and 
Hispanic (33%) patients had a higher proportion of tumors located within the rectum.  Combined 
with the growing evidence on tumor subtypes, our finding of racial differences in the age and 
tumor site distribution of CRC make a compelling argument for distinct mechanisms driving 
CRC progression in various population subgroups.  
A higher proportion of younger patients (both stages II and III) in our study received 
“optimal” care, including better nodal counts from surgery, treatment at academic medical 
centers, clinical trial enrollment, chemotherapy, and radiation therapy, compared to the two 
older groups of patients. Even in the setting of stage II colon cancer, where the absolute benefit 
of chemotherapy is very small, the vast majority of young patients (71%) received adjuvant 
therapy. Many of the younger stage II patients treated with chemotherapy had high risk features, 
including T4 tumors (16% vs. 9%), low-grade histology (22% vs. 19%), and inadequately 
sampled (<12) lymph nodes (33% vs. 28%), compared to younger patients who did not receive 
therapy (data not shown). Despite more aggressive treatment, some research suggests younger 
CRC patients have a worse prognosis than older patients of the same stage, or overall survival 
is similar between the two groups.18,21,23,24,26,33,34,46 A recent study47 of colon cancer patients in 
the National Cancer Data Base found no difference in the relative survival of younger and older 
patients, even though younger patients more frequently received chemotherapy. Our findings 
and the results of others may reflect physician preferences to ambitiously treat disease simply 
based on younger age at presentation. 
A strength of our study is the population-based sample. Data from POC studies offer a 
number of unique advantages for conducting population-based epidemiologic research because 
each participating registry area has a defined population, and detailed tumor and treatment 
information was abstracted from patient medical records and verified by treating physicians. 
Previous research has been limited to single institution studies or relied on small sample sized, 
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in which results generally reflect the distribution of characteristics of patients treated at that 
institution rather than true differences in younger and older CRC patients. POC data also 
provide a greater breadth and depth of information than that available solely from medical 
claims and/or SEER registries. This was particularly true for our assessment of receipt of 
chemotherapy and radiation therapy, where doctor verification substantially improved the 
completeness of treatment ascertainment. Further, the large size and ethnic diversity of this 
study population were strengths that enabled us to examine CRC characteristics within 
population subgroups by race/ethnicity.  
Our study population was limited to stages II and III patients, and there may be different 
characteristics of younger CRC patients when considering early-stage or metastatic disease. 
For example, we observed only slight differences in county-level socioeconomic indicators 
among younger and older patients, but a relationship between CRC and socioeconomic status 
has been demonstrated most consistently in late-stage disease.106-109 The increase in the 
number of younger patients diagnosed with stages II and III CRC in our study may also be a 
reflection of stage migration (i.e., some cases once considered stage I would now be classified 
as stage II); however, evidence has consistently shown meaningful increases in all stages of 
young-onset CRC.68 In addition, we did not have information on genetic predisposition to CRC, 
either by hereditary syndrome or a first-degree relative with a history of CRC. These data may 
have helped explain changes in the distribution of young-onset CRC over time, but the 
prevalence of these syndromes in younger populations remains very low.13 Finally, there were 
few patients who received MSI testing, which precluded our ability to report the prevalence of 
molecular markers in the study population. Although collection efforts have likely improved since 
2010, and SEER now includes site-specific factors on MSI and KRAS mutation, our study 
highlights the continued need for robust sources of molecular data at the population-level.  
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The increasing incidence of CRC in younger populations—and the poorer prognosis of 
young patients—may reflect differences in risk factors for the development of CRC rather than 
disparities in detection and treatment. Results of this study demonstrate important differences in 
the distribution of young-onset CRC by race/ethnicity. These differences may be attributable to 
lifestyle-related risk factors, such as a higher prevalence of obesity, physical activity levels, and 
cultural differences in diet. Our findings support the effort to understand CRC as a 
heterogeneous disease based on age, race/ethnicity, and molecular markers. 
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Table 4.1: Characteristics of 6,862 patients diagnosed with stages II and III colorectal cancer, 
1990-2010, by age at diagnosis 
    
 Age <50 Years  
(n=871) 
Age 50-69 Years 
(n=3,018) 
Age ≥70 Years 
(n=2,973) 
 n weighted1 % n weighted1 % n weighted1 % 
Demographic  
Characteristics 
      
Sex       
Male 472 54.0 1685 56.0 1377 44.3 
Female 399 46.0 1333 44.0 1596 55.7 
Race/ethnicity       
White, non-Hispanic 317 61.4 1490 71.5 1810 81.0 
Black, non-Hispanic 200 13.3 634 11.2 449 6.7 
Hispanic 189 14.7 495 9.7 386 6.7 
Other 165 10.5 399 7.6 328 5.6 
Insurance       
Private/HMO/VA/Other 637 78.9 2214 76.8 1848 67.2 
Medicare (only) 127 1.0 351 9.1 685 23.0 
Medicaid (any) 13 14.4 254 10.6 358 9.2 
None 75 5.8 128 3.6 21 0.6 
Clinicopathologic 
Features 
      
Tumor Site       
Right Colon 176 22.4 679 31.9 951 46.4 
Left Colon 116 15.6 332 15.1 379 15.4 
Sigmoid Colon 137 25.1 536 22.2 482 20.2 
Rectum2 433 36.9 1456 30.8 1140 18.0 
Stage at Diagnosis       
Stage II 360 42.2 1437 48.7 1532 54.2 
Stage III 511 57.8 1581 51.3 1441 45.8 
Histologic Grade       
Well/moderately 
differentiated 
640 78.7 2352 82.2 2216 73.4 
Poorly/undifferentiated 186 21.3 526 17.8 641 26.6 
Mucinous 
Adenocarcinoma 
110 11.1 293 9.5 321 11.5 
Signet Ring Cell 
Carcinoma 
12 0.8 28 0.7 29 1.2 
MSI Testing Performed3       
No 140 72.7 540 90.3 423 92.9 
Yes 68 27.3 83 9.7 44 7.1 
Treatment       
Surgery Type       
Local Excision 6 0.7 16 0.5 16 0.4 
Partial Colectomy 480 56.4 1619 50.5 1466 41.1 
Subtotal Colectomy 240 30.7 839 38.4 1080 50.6 
Total Colectomy 98 9.1 346 6.5 249 3.8 
Total Proctocolectomy 38 2.4 163 3.4 139 3.5 
Other 9 0.7 35 0.7 23 0.6 
Laparoscopic Surgery4        
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No 583 77.2 1763 78.0 1646 82.7 
Yes 130 22.8 380 22.0 283 17.3 
Lymph Nodes Examined       
0 24 1.8 89 2.0 73 1.7 
1-11 258 25.8 1302 37.8 1499 45.0 
≥12 560 72.4 1537 60.2 1297 53.3 
Positive Margins       
No 772 94.5 2672 93.5 2558 95.0 
Yes 47 5.5 133 6.5 146 5.0 
Received Chemotherapy       
No 169 18.5 943 32.5 1848 66.2 
Yes 683 81.5 2029 67.5 1061 33.8 
Received Radiation 
Therapy5  
      
No 112 25.0 494 34.1 699 57.4 
Yes 321 75.0 962 65.9 441 42.6 
Socioeconomic 
Indicators (Census 
Tract-Level) 
      
SES Index6       
Quintile 1 122 15.8 378 18.5 322 17.2 
Quintile 2 113 21.4 350 20.3 279 20.6 
Quintile 3 109 19.5 322 24.7 259 17.5 
Quintile 4 113 20.8 251 16.0 276 22.2 
Quintile 5 104 22.6 275 20.6 238 22.6 
Socioeconomic 
Indicators (Patient-
Level) 
      
Hospital Type       
Private 67 11.9 238 7.2 247 10.1 
Government 182 16.1 540 17.4 387 13.5 
Nonprofit 621 72.0 2212 75.4 2313 76.4 
Teaching Hospital       
No 370 45.2 1397 51.9 1564 53.9 
Yes 498 54.8 1585 48.1 1374 46.1 
Total Bed Size       
<200 194 26.1 676 25.1 710 27.2 
200-400 336 39.3 1330 43.2 1335 43.6 
≥400 339 34.6 982 31.6 895 29.2 
Clinical Trial Enrollment       
No 728 91.7 2494 94.4 2583 98.2 
Yes 67 8.3 179 5.6 74 1.8 
NOTE: Table does not include patients who did not undergo cancer-directed surgery (n=167) or with 
incomplete staging information (n=35); no variable had more than 10% missing data, missing 
observations range from 35 (tumor site) to 737 (clinical trial enrollment)  
Abbreviations: VA, Veterans Affairs; MSI, microsatellite instability; SES, socioeconomic status 
1 Proportions weighted by sampling fraction 
2Rectal includes both rectum and rectosigmoid junction 
3Microsatellite instability collected in 2010 only 
4Laproscopic colectomy collected in 1995, 2000, 2005, and 2010 
5Receipt of radiation therapy limited to rectal cancer patients (n=3,029); includes postoperative and 
preoperative radiation 
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6Socioeconomic status based on composite census-tract level indicators from Census 2000 and 
American Community Survey 2005-2009; limited to data collection years 2000, 2005, and 2010 and does 
not include Louisiana 
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Table 4.2: Characteristics of 706 younger (age <50 years) patients diagnosed with stages 
II and III colorectal cancer, 1990-2010, by race/ethnicity  
 
  
 NH White  
(n=317) 
NH Black  
(n=200) 
Hispanic  
(n=189) 
 n weighted1 % n weighted1 % n weighted1 % 
Sex       
Male  184 54.8 109 52.1 94 52.7 
Female 133 45.2 91 47.9 95 47.3 
Insurance2       
Private/HMO/VA/Other 275 86.1 129 60.7 114 67.7 
Medicaid (any) 22 10.8 48 26.1 35 19.6 
None 11 3.0 16 10.5 29 9.8 
Year of Diagnosis       
1990/91 114 16.5 22 13.6 5 1.4 
1995 42 8.8 38 10.1 36 6.5 
2000 27 9.4 28 11.8 32 13.3 
2005 75 33.5 59 30.7 50 27.6 
2010 59 31.9 53 33.8 66 51.2 
Tumor Site       
Right Colon 49 19.4 62 38.5 42 26.3 
Left Colon 28 13.8 29 19.9 29 16.4 
Sigmoid Colon 44 25.9 29 17.8 33 24.3 
Rectum 193 40.9 80 23.8 83 32.9 
Mucinous Histology 30 10.4 36 17.7 29 11.8 
Histologic Grade       
Well/moderately 
differentiated 
246 80.7 146 81.7 140 79.2 
Poorly/undifferentiated 57 19.3 39 18.3 40 20.8 
Stage at Diagnosis       
Stage II 118 42.7 86 47.4 87 38.0 
Stage III 199 57.3 114 52.6 102 62.0 
MSI Testing Performed3       
No 36 74.6 32 68.4 42 76.5 
Yes 14 25.4 20 31.6 18 23.5 
Received Chemotherapy4       
No 50 15.2 50 27.8 36 18.8 
Yes 261 84.8 147 72.2 147 81.2 
Received Radiation 
Therapy5 
      
No 61 27.9 16 16.8 17 16.7 
Yes 132 72.1 64 83.2 66 83.3 
SES Index6       
Quintile 1 11 7.7 46 37.9 45 28.0 
Quintile 2 30 22.5 26 24.2 34 20.9 
Quintile 3 26 16.3 18 16.3 30 27.4 
Quintile 4 37 21.8 20 16.1 25 17.0 
Quintile 5 43 31.7 12 5.4 8 6.7 
Abbreviations: NH, non-Hispanic; VA, Veterans Affairs; MSI, microsatellite instability; SES, 
socioeconomic status 
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1 Proportions weighted by sampling fraction 
2Percentages do not add to 100 because some younger patients were insured through Medicare; cell 
sizes too small (<5) to report  
3MSI testing collected in 2010 only 
4Reciept of chemotherapy includes both neoadjuvant and adjuvant (or both) chemotherapy 
5Receipt of radiation therapy limited to rectal cancer patients (n=356); includes postoperative and 
preoperative radiation 
6Socioeconomic status based on composite census-tract level indicators from Census 2000 and 
American Community Survey 2005-2009; limited to study years 2000, 2005, and 2010 and does not 
include Louisiana  
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Table 4.3: County-level socioeconomic indicators of 6,862 patients diagnosed with stages II and 
III colorectal cancer, 1990-2010, by age at diagnosis 
 
 Age <50 Years 
(n=871) 
Age 50-69 Years 
(n=3,018) 
Age ≥70 Years 
(n=2,973) 
 n weighted1 % n weighted1 % n weighted1 % 
Per Capita Income2       
<$32,000 133 15.4 665 23.2 718 24.8 
$32,000-50,000 575 66.0 1909 62.8 1818 58.1 
>$50,000 163 18.6 444 14.0 437 17.1 
Median  39637 38380 38337 
Median Household Income2       
<$50,000 176 18.8 736 24.2 691 22.8 
$50,000-75,000 558 67.6 1870 63.1 1838 61.9 
>$75,000 137 13.6 412 12.7 444 15.3 
Median  57755 56931 57745 
% Living in Poverty3       
<10 214 32.6 619 30.0 626 36.5 
10-19 409 55.5 1165 54.4 1037 52.9 
≥20 99 11.9 387 15.6 299 10.7 
Median  12.8 12.7 11.9 
% Less than High School       
<10 378 37.3 1471 43.3 1614 48.7 
10-19 377 45.9 1155 39.8 1042 36.4 
≥20 116 16.8 392 16.9 317 14.8 
Median  12.1 11.4 10.2 
Unemployment Rate (%)       
<5 273 30.6 976 32.6 1090 36.5 
5-9 437 45.7 1550 43.1 1499 45.2 
≥10 161 23.7 492 24.3 384 18.3 
Median  5.8 5.7 5.3 
Total Physicians per 
100,000 
      
<200 209 26.7 793 30.6 801 28.4 
200-400 473 52.3 1560 48.4 1440 48.6 
≥400 189 21.0 665 21.0 732 23.0 
Median  268.2  268.3 268.4 
Total Gastroenterologists 
per 100,0003 
      
<3 201 30.3 625 32.0 581 32.0 
3-5 310 41.7 957 42.6 845 38.1 
>5 211 28.0 589 25.5 536 29.9 
Median  3.9  3.7 3.7 
NOTE: Cutpoints based on approximate tertiles 
1 Proportions weighted by sampling fraction 
2Adjusted to 2010 dollars 
3Poverty and total number of gastroenterologists not collected in 1990/91 
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Table 4.4: Receipt of chemotherapy and radiation therapy among 6,862 patients diagnosed with 
stages II and III colorectal cancer, 1990-2010, by age and stage at diagnosis  
 
 Stage II (n=3,329) Stage III (n=3,533) 
 Age <50 Age 50-69 Age ≥70 Age <50 Age 50-69 Age ≥70 
 n (wt. %) n (wt. %) n (wt. %) n (wt. %) n (wt. %) n (wt. %) 
Received 
Chemotherapy1 
      
Colon Cancer        
No 71 (29.2) 465 (57.4) 809 (86.0) 43 (18.0) 156 (17.9) 439 (50.9) 
Yes 121 (70.8) 281 (42.6) 131 (14.0) 180 (82.0) 621 (82.1) 390 (49.1) 
Rectal Cancer       
No 28 (17.6) 216 (34.3) 323 (52.3) 24 (6.0) 101 (9.1) 264 (42.3) 
Yes 128 (82.4) 444 (65.7) 225 (47.7) 248 (94.0) 674 (90.9) 307 (57.7) 
Received Radiation 
Therapy2 
      
Rectal Cancer       
No 45 (28.5) 241 (39.0) 342 (57.1) 67 (23.3) 253 (30.1) 357 (57.8) 
Yes 112 (71.5) 431 (61.0) 214 (42.9) 209 (76.7) 531 (69.9) 227 (42.2) 
NOTE: Proportions weighted by sampling fraction 
Abbreviations: wt, weighted 
1Reciept of chemotherapy includes both neoadjuvant and adjuvant (or both) chemotherapy 
2Receipt of radiation therapy includes postoperative and preoperative radiation 
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CHAPTER 5 
RESULTS: AN AGE-PERIOD-COHORT ANALYSIS OF THE CHANGING INCIDENCE 
PATTERNS OF COLORECTAL CANCER2 
 
A. INTRODUCTION 
The overall incidence and mortality of colorectal cancer (CRC) has declined in the U.S. 
in the past two decades.8 In 1975, CRC incidence was 56.5 per 100,000 compared to 39.8 per 
100,000 in 2012.94 Incidence rates declined by 3.9% per year among adults age 50 years and 
older from 2001-2010, with the steepest declines among those over the age of 65. CRC 
mortality rates similarly declined 3.0% annually in both men and women during the same 
period.8 Much of this decrease has been attributed to the use of screening.9 Regular screening 
with the fecal occult blood test, sigmoidoscopy, and colonoscopy facilitates earlier detection of 
CRC and lowers incidence and mortality through removal of premalignant polyps.11 Current 
guidelines recommend screening begin at age 50 for those at average-risk of CRC.10  
 Although CRC incidence and mortality rates in the total population have improved, 
recent evidence suggests the incidence of CRC in younger adults (age <50 years) is rapidly 
increasing. Incidence rates in younger populations have consistently increased since the 1970s, 
with annual increases of up to 4% for rectal and 2% for colon cancer.2-6,17,68 Despite the overall 
population trends in aging, by 2030, approximately 11% of colon and 23% of rectal cancers may 
be diagnosed in patients younger than the current screening age.68 
 
                                                          
2 At the time of this writing, a condensed version of this chapter has been submitted to JAMA. Authors 
include the committee members listed on the title page.  
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Reasons for the increase in young-onset CRC are poorly understood. Several risk 
factors for CRC, including unhealthy diet, obesity, physical inactivity, and smoking, have been 
proposed as the major drivers of the increase in younger adults.48,49 Meta-analyses demonstrate 
significant associations between CRC risk and red and processed meat consumption,50,51 
adiposity (including measures of body mass index, waist circumference, and waist-to-hip 
ratio),52,54,110 sedentary behavior and physical inactivity,55 and cigarette smoking.56 However, the 
extent to which changes in the prevalence of these risk factors explain increases in in the 
incidence of young-onset CRC has not been studied.  
 Given the changing incidence patterns of CRC, in which incidence has decreased in 
screening-aged populations but increased in younger populations, we used age-period-cohort 
(APC) analysis to estimate the differential contributions of age, period, and birth cohort to the 
incidence of CRC. APC analysis combines information on age, time period of observation, and 
birth cohort to track health outcomes over time. We also described period and cohort trends in 
the prevalence of CRC risk factors (obesity, physical inactivity, current smoking) in younger 
populations.  
B. METHODS 
Data Sources 
CRC Incidence. Incidence of CRC was derived from the National Cancer Institute’s 
(NCI) Surveillance, Epidemiology, and End Results (SEER) program. The SEER program 
routinely collects data on patient demographics, primary tumor site, tumor morphology, and 
stage for all cancers diagnosed in defined geographic regions. SEER 9 registries consists of 
Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco—Oakland, Seattle—
Puget Sound, and Utah, approximately 9.5% of the U.S. population. CRC was defined 
anatomically as located in the colon (ascending, transverse, descending, hepatic flexure, 
 57 
 
splenic flexure, sigmoid colon; International Classification of Disease for Oncology, Third Edition 
[ICD-O-3] codes 18.2-18.9) or rectum (rectum, rectosigmoid junction; ICD-O-3 codes 19.9, 
20.9). Incidence rates per 100,000 persons within the population were analyzed from 1973-2012 
for four race/sex subgroups (white males, white females, black males, black females).  
Prevalence of CRC Risk Factors. To complement incidence data, we also described 
period and cohort trends in the prevalence of common risk factors for CRC among younger 
adults (age <50 years), including obesity, physical inactivity, and smoking. Obesity prevalence 
was determined using data from the National Health and Nutrition Examination Survey 
(NHANES) phases I (1971-1975), II (1976-1980), and III (1988-1994) and the continuous cycles 
(1999-2012). NHANES is the only study that provides estimates on anthropometric measures 
for the U.S. population. Data collection procedures include a standardized physical examination, 
where a trained health technologist collects a complete set of anthropometric measures (e.g., 
weight, height, upper leg, and arm length) from survey participants. Obesity was measured as a 
body mass index (BMI) ≥ 30 kg/ m2. 
Prevalence of physical inactivity was derived from the Behavioral Risk Factor 
Surveillance System (BRFSS) during years 1984-2010. Surveys are administrated continuously 
through the year by state health departments via random digit dialing. BRFSS provides a 
consistent measure of physical inactivity across all survey years, defined as no leisure-time 
activity or exercise in the last 30 days (i.e., “During the past month, did you participate in any 
physical activities or exercises such as running, calisthenics, golf gardening, or walking for 
exercise?”). Starting in 2011, BRFSS changed the weighting methodology and included cell 
phone only respondents in the sampling frame; data from 2011 forward are not directly 
comparable to previous survey years. Therefore, we used 2010 data as the estimate for the 
prevalence of physical activity during the corresponding 2010-2012 period. 
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We obtained the prevalence of current smoking from the National Health Interview 
Survey (NHIS) in years 1974, 1976-1980, 1983, 1985, 1987-1988, 1990-1995, and 1997-2012. 
Adult tobacco use was first measured on the NHIS as part of the 1965 smoking supplement and 
has been included annually in the adult health behaviors section of NHIS since 1997. The basic 
NHIS cigarette smoking questions consist of a screener question, “Have you ever smoked at 
least 100 cigarettes in your entire life?” and follow-up questions about current smoking 
practices. Although follow-up questions have varied slightly across survey years (e.g., from “Do 
you smoke now?” to “Do you smoke every day, some days, or not at all?”), the same smoking 
status variable recodes are included in the public use data files. Participants are categorized as 
current (including both every day smoker and some day smoker), former, or never smokers.  
To estimate the prevalence of period-specific risk factors, we pooled prevalence 
estimates across all ages (age ≥ 21 years) for the four race/sex subgroups (white males, white 
females, black males, black females) for the corresponding NHANES, BRFSS, and NHIS years 
of data collection.  Similarly, we estimated the prevalence of cohort-specific risk factors by 
averaging the prevalence in each birth cohort across the same periods of data collection. 
Because surveys were not conducted in certain years (e.g., NHANES data were not collected in 
1981-1987), we interpolated prevalence by averaging the prevalences for the previous and 
subsequent periods or cohorts. To account for the possibility that CRC incidence increases 
linearly with BMI (vs. a threshold effect of BMI ≥ 30), we also estimated period- and cohort-
specific mean and median BMI using a similar approach.  
Statistical Analysis 
 Two-way graphical displays of age by time period, time period by age, and birth cohort 
by time period incidence rates were first created to describe trends in incidence across age, 
period, and cohort.  Incidence trends were examined overall and separately in the younger (age 
<50 years) population.  
 59 
 
Independent age (i.e., distribution of the outcome across the life course due to aging), 
period (i.e., secular trends in the prevalence of an outcome that occur in all ages), and birth 
cohort effects (i.e., variation in the outcome among those born in or around the same year) can 
be estimated with a variety of statistical methods. We used Poisson cross-classified random 
effects modeling (CCREM) specifications of hierarchical age-period-cohort (HAPC) models that 
account for variations in multi-level data by nesting age-specific incidence rates within periods 
and birth cohorts. The HAPC models avoid the identification problem111 of linear APC regression 
models, in which age, period, and cohort are perfectly collinear, because the three effects are 
not assumed to be linear and additive at the same level of analysis.81,87 CCREM allows for the 
possibility that individuals within the same periods and birth cohorts share some unobserved 
random variance. Although only a longitudinal panel study design provides data from true birth 
cohorts that follow identical individuals over time, this design allows for a synthetic cohort 
approach, used often in demography research.81 The synthetic cohort approach has the 
advantage of simultaneously testing age and period effects because it is based on nationally 
representative data (e.g., SEER) collected regularly from one period to the next and covers 
several decades. We developed separate models for the overall, younger (age <50 years), and 
older (age ≥50 years) populations. We also plotted the random effects coefficients from these 
models to facilitate interpretation of the period and/or cohort effects. Model components and 
parameters are defined in detail in Chapter 3.  
Birth cohort and period were divided into approximate 5-year categories for 21 birth 
cohorts and 9 periods. Continuous age was centered at the mean to reduce the association 
between the linear and quadratic age terms. Beta coefficients for the fixed-level effects (i.e., 
race, sex, and age) can be interpreted as the increase in incidence for every one-unit increase. 
All statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North 
Carolina). 
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C. RESULTS  
 Two-way descriptive graphs of age, period, and cohort trends are shown in Figures 5.1-
5.6. We created separate graphs of trends for the overall population and for younger ages (<50 
years). As shown in Figure 5.1, age-period incidence rates in the overall population increased 
with increasing age. There were dramatic declines in incidence among older individuals by time 
period. The highest incidence rates for these older age groups were in 1973-74 and lowest in 
2010-12. In younger ages (age <50 years), however, incidence rates were similar in all time 
periods (Figure 5.2). A similar trend was observed with period-age incidence rates (Figure 5.3). 
There were consistent declines in incidence for those ages 65 years and older after 1985, with 
the steepest decreases in the oldest age groups (ages 75-79, 80-85, 85+). In the younger 
population (Figure 5.4), incidence remained relatively flat over time, although there were small 
increases in the more recent time periods. Age-birth cohort incidence rates (Figure 5.5) 
increased in the early birth cohorts (1885-1925) for ages 65 years and older. Starting with 
approximately the 1920-24 birth cohort, incidence rates generally decreased across successive 
cohorts. Incidence rates in the younger population (age <50 years) slightly increased by birth 
cohorts, especially after the 1945-49 birth cohort (Figure 5.6).  
Prevalence of CRC risk factors across period and birth cohort are shown for the four 
race/sex subgroups in Figures 5.7-5.16. For all race/sex subgroups, obesity increased across 
time periods, from 12.9% (1975-79) to 34.6% (2010-12) (Figure 5.7). Period-obesity prevalence 
was consistently higher among black females compared to other race/sex subgroups. Similar 
results were observed for mean (Figure 5.8) and median (Figure 5.9) BMI. Trends in cohort-
obesity were more variable, although prevalence generally increased across successive birth 
cohorts, starting with individuals born around 1950 (Figure 5.10). The lowest prevalence was 
among white males in the 1935-39 birth cohort (10.8%), and the highest was black females in 
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the 1980-84 cohort (51.2%). There was a similar pattern for median (Figure 5.11) and mean 
(Figure 5.12) BMI. 
Physical inactivity remained relatively stable over time in all race/sex subgroups 
combined, from 21.1% in 1985-89 to 20.1% in 2010-12 (Figure 5.13). There were small 
increases from 1985-89 to 1995-99 (24.6%) and subsequent decreases through the end of the 
study period. Prevalence was highest among black females in all years. The trend in cohort-
physical inactivity was more consistent, with general declines across successive birth cohorts 
(Figure 5.14). For the majority of race/sex subgroups, the prevalence of cohort-physical 
inactivity was highest in the 1940-44 birth cohort (white males: 29.7%, white females: 28.1%, 
black males: 38.7%, black females: 38.8%).  
For all race/sex subgroups, the prevalence of period-smoking decreased dramatically 
over time (Figure 5.15). The overall prevalence of current smoking was 43.5% in 1973-4 
compared to 24.8% in 2010-12. Before 1990-94, smoking prevalence was highest among black 
males (59.6% in 1973-74 to 36.2% in 1990-94), but in more recent years, prevalence was 
highest among white males (31.3% 1995-99 to 27.2% in 2010-12). There were similar declines 
in smoking by birth cohort (Figure 5.16). Prevalence decreased across successive birth cohorts 
for all race/sex subgroups, although it increased slightly among white males in the youngest 
birth cohorts (1980-84).  
Results of the CCREM analysis in the overall population are shown in Table 5.1 (Model 
A). Incidence was higher among blacks (vs. whites, β= 0.20, p <0.001) and lower among 
females (vs. males, β= -0.32, p <0.001). There was a significant age effect, where incidence 
rates increased 11% with each one-year increase in age (β= 0.11, p<0.001). There were also 
significant period (σ= 0.02, p= 0.02) and birth cohort (σ=0.07, p<0.001) effects. Incidence 
increased from the period 1973-74 to 1985-89 and then decreased through 2010-12 (Figure 
5.17), independent of the birth cohort and age. Similarly, when adjusting for time period and 
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age, incidence increased slightly from the 1985-89 to the 1900-04 birth cohorts and declined 
through the 1945-49 cohort, with larger increases again in the most recent cohorts (Figure 
5.18). In the stratified analysis by age group, incidence was also higher among blacks and lower 
among females in the both the younger (age <50 years; Table 5.1, Model B) and older (age ≥50 
years; Table 5.1, Model C) populations. Age (β= 0.15, p<0.001) and birth cohort (σ= 0.01, p= 
0.04) were statistically significant in the model restricted to age <50 years, but period was not 
(σ= 0.002, p= 0.09). In the older population, there were independent age (β= 0.10, p<0.001), 
period (σ= 0.02, p= 0.02), and birth cohort (σ= 0.04, p= 0.004) effects. 
D. DISCUSSION  
Our study shows large decreases in CRC incidence for older populations across time 
periods and birth cohorts that have important implications for the role of CRC screening. We 
observed a dramatic decline in incidence from the earliest (1973-74) to most recent (2010-12) 
time periods that was limited to the screening-age population. Unlike screening for other 
cancers (e.g., breast, prostate), CRC screening reduces incidence via polypectomy and removal 
of premalignant lesions. Population-based screening was first introduced in the late 1980s when 
the NCI developed working guidelines for the early detection of cancer112 and was later included 
in the 2000 Objectives for the Health of the Nation.  The use CRC screening has since 
increased (largely driven by the use of colonoscopy),66,67,113,114 but the extent to which it explains 
declines in CRC incidence continues to be debated. Some argue screening accounts for much 
of the improvement in CRC outcomes, where the benefits of screening observed in clinical trials 
have led to significant reductions in both incidence and mortality rates.9,115-117 However, others 
suggest it has had only a modest impact, and changes in risk factors may be more important 
than the adoption of screening.115,118 Our results provide compelling evidence to suggest that 
reductions in incidence over time, which begin precisely at age 50, cannot be solely attributed to 
biology or risk factors. Rather, the striking finding that incidence curves diverge sharply in 
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screening-age populations demonstrate a screening effect in a way that has not been previously 
described.   
Differences in the age distribution of CRC that have been frequently observed, in which 
the proportion of CRC patients diagnosed at younger ages is increasing, may simply be a 
consequence of declines in CRC in older adults (i.e., due to screening). The results of our study 
demonstrate only a small absolute increase in CRC incidence in younger populations. Young-
onset CRC has gained the attention of many researchers and media outlets, in part because of 
the large relative increases (i.e., percentage change) in incidence that have been reported. 
Presenting increases in incidence rates in exclusively relative terms can have a dramatic effect 
on their interpretation and may lead to confusion about the magnitude of such increases. Our 
analyses show an increase of only one or two additional cases per 100,000 persons over a 30-
year time period, while others have simultaneously suggested large relative increases of over 
100%.68 Some professional organizations have promoted changing screening guidelines to 
begin average-risk screening at a younger age.1 Most recently, the American College of 
Gastroenterology119 recommends screening begin at age 45 (vs. 50) for blacks based on 
relative differences in incidence,120 and it may not be long before similar recommendations are 
made in the overall population. Our findings, however, highlight the importance of considering 
absolute (vs. relative) measures when making public health policy decisions. Relative measures 
of effect are expressed as a dimensionless ratio and do not capture information on background 
risk or base rates of health, and as a result, they may overestimate the perception of the extent 
to which young-onset CRC has increased.  
Despite small increases in incidence, we observed a cohort effect in younger 
populations. Yet, in contrast to the incidence patterns in older adults, there was not a period 
effect. This finding gives additional support to the hypothesis that there may be different 
mechanisms involved in the development of CRC across the life course (see Chapter 4). Cohort 
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effects are evidence in many cancers and chronic diseases because birth cohorts often have 
different exposures to behavioral and environmental risk factors. When cumulative exposures or 
exposures during vulnerable ages to risk factors (known or unknown) vary in prevalence from 
one generation to the next, incidence rates in the population may also vary substantially by birth 
cohort. For example, the increase in lung cancer incidence and mortality through the 1990s and 
subsequent decline has been widely attributed to the parallel trends in smoking by birth cohort.81 
In gastrointestinal malignancies, it has been suggested that the decreasing cohort trends in 
Helicobacter pylori colonization,121,122 which is inversely associated with risk of esophageal 
adenocarcinoma123 and a known cause of gastric cancer,124 may contribute to changes in 
incidence patterns.125 Our study underscores the need for a better understanding of the critical 
factors involved with cohort-mechanisms, such as childhood obesity or changes in microbiota, 
which may be related to young-onset CRC.  
The role of modifiable risk factors in the increase of young-onset CRC is not clear. 
Population surveys can be helpful in efforts to understand the context of incidence trends, but 
they do not provide the level of detail needed to identify risk factors for disease. Ecological data 
describes characteristics of a group, and conclusions cannot be made regarding individuals.  
Consistent with others,126 our analysis of NHANES data shows increases in the prevalence of 
obesity in younger populations across both time periods and birth cohorts. It may be that 
increases in BMI, especially at younger ages, account for some of the increases in incidence, 
but the mechanisms involved in obesity and cancer risk have not been fully elucidated. For 
example, accumulating evidences shows there are differences in the relevant measure of 
adiposity by race/ethnicity, where waist-hip-ratio may be a better marker of CRC risk in black 
patients than BMI.127,128 Second, we were surprised to find the prevalence of physical inactivity 
(based on BRFSS data) decrease by period and cohort. The relationship between CRC and 
sedentary behavior and/or physical activity is consistent across multiple studies and in different 
 65 
 
settings and populations,55 but the trend data do not correspond with changes in incidence. This 
may be a reflection of the challenges that arise when assessing physical activity with population 
surveys. Guideline recommendations have changed in the U.S. over time,84 which has 
subsequently heightened awareness of what can be considered physical activity (e.g., 
gardening, yardwork). Finally, the results demonstrate overall declines in smoking trends, 
although there were some modest increases in smoking behavior among white males in the 
most recent birth cohorts. Large cohort studies suggest the elevated risk for rectal cancer 
among smokers may drive the association between smoking behavior and overall CRC risk.129 
Cancer registry data similarly show tumors in the rectum (vs. colon) are more common in young, 
white males.2 Collectively, findings related to trends in obesity, physical inactivity, and smoking 
point to other factors that may increase risk of young-onset CRC. 
In summary, our results suggest there are differential effects of time period and birth 
cohort in the changing incidence patterns of CRC. Declines in incidence among older 
populations can be attributed to screening, which was clearly demonstrated by the sharp break 
in incidence curves at age 50. The factors responsible for increases in young-onset CRC, albeit 
small on an absolute scale, remain unknown. It may be that other risk factors not measured 
through population surveys, such as intestinal microbiota, explain changes in incidence. When 
considered alongside evidence on the differences in the racial and tumor site distribution of 
young- and older-onset CRC, this study provides strong support for different etiologies of CRC 
by age.   
  
  
 
Table 5.1: Poisson HAPC-CCREM estimates of incidence rates of colorectal cancer, SEER 9, 1973-2012 
      
 Model A (all ages)  Model B (age <50 years)  Model C (age ≥ 50 years) 
Fixed Effects Coefficient SE p  Coefficient SE p  Coefficient SE p 
Model for Mean            
Intercept -7.04 0.07 <0.001  -10.08 0.04 <0.001  -7.02 0.071 <0.001 
Age (linear, 
centered) 
0.11 <0.001 <0.001  0.15 0.002 <0.001  0.10 <0.001 <0.001 
Age (quadratic) -0.002 <0.001 <0.001  -0.001 <0.001 <0.001  -0.001 <0.001 <0.001 
Female Sex -0.32 0.003 <0.001  -0.12 0.01 <0.001  -0.33 0.003 <0.001 
Black Race 0.20 0.01 <0.001  0.37 0.02 <0.001  0.18 0.01 <0.001 
Variance Components Variance SE p  Variance SE p  Variance SE p 
Cohort            
Intercept 0.07 0.02 0.001  0.01 0.01 0.04  0.04 0.01 0.004 
Period            
Intercept 0.02 0.01 0.02  0.002 0.002 0.09  0.02 0.01 0.02 
Abbreviations: HAPC-CCREM, hierarchical age-period-cohort cross classified random effects model; SE, standard error 
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Figure 5.1. Age by time period incidence rates of colorectal cancer, all ages, SEER 9, 1973-
2012 
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Figure 5.2. Age by time period incidence rates of colorectal cancer, age 21-49 years, SEER 9, 
1973-2012  
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Figure 5.3. Time period by age incidence rates of colorectal cancer, all ages, SEER 9, 1973-
2012 
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Figure 5.4. Time period by age incidence rates of colorectal cancer, ages 21-49 years, SEER 9, 
1973-2012 
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Figure 5.5. Birth cohort by age incidence rates of colorectal cancer, all ages, SEER 9, 1973-
2012 
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Figure 5.6. Birth cohort by age incidence rates of colorectal cancer, ages 21-49 years, SEER 9, 
1973-2012 
 
  
73 
 
Figure 5.7. Prevalence of obesity by time period for four race/sex subgroups, ages 21-49 years, 
National Health and Nutrition Examination Survey, 1973-2012 
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Figure 5.8. Mean body mass index by time period for four race/sex subgroups, ages 21-49 
years, National Health and Nutrition Examination Survey, 1973-2012 
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Figure 5.9. Median body mass index by time period for four race/sex subgroups, ages 21-49 
years, National Health and Nutrition Examination Survey, 1973-2012 
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Figure 5.10. Prevalence of obesity by birth cohort for four race/sex subgroups, ages 21-49 
years, National Health and Nutrition Examination Survey, 1973-2012 
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Figure 5.11. Mean body mass index by birth cohort for four race/sex subgroups, ages 21-49 
years, National Health and Nutrition Examination Survey, 1973-2012 
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Figure 5.12. Median body mass index by birth cohort for four race/sex subgroups, ages 21-49 
years, National Health and Nutrition Examination Survey, 1973-2012 
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Figure 5.13. Prevalence of physical inactivity by time period for four race/sex subgroups, ages 
21-49 years, Behavioral Risk Factor Surveillance System, 1984-2011 
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Figure 5.14. Prevalence of physical inactivity by birth cohort for four race/sex subgroups, ages 
21-49 years, Behavioral Risk Factor Surveillance System, 1984-2011 
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Figure 5.15. Prevalence of current smoking by time period for four race/sex subgroups, ages 
21-49 years, National Health Interview Survey, 1974-2012 
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Figure 5.16. Prevalence of current smoking by birth cohort for four race/sex subgroups, ages 
21-49 years, National Health Interview Survey, 1974-2012 
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Figure 5.17. Predicted incidence of colorectal cancer by time period, all ages, SEER 9, 1973-
2012 
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Figure 5.18. Predicted incidence of colorectal cancer by birth cohort, all ages, SEER 9, 1973-
2012 
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CHAPTER 6 
RESULTS: PATTERNS OF COLONOSCOPY USE IN YOUNGER ADULTS 
 
A. INTRODUCTION 
Recent research suggests the incidence of colorectal cancer (CRC) in younger 
populations (age <50 years) is rapidly increasing. Data from the Surveillance, Epidemiology, 
and End Results (SEER) program show the incidence of CRC has increased by up to 5% per 
year among younger adults since the 1970s.1-6,68 Current projections suggest that, by 2030, 
approximately 11% of all colon and 23% of all rectal cancers may be diagnosed in patients 
younger than age 50.68  
Trends in cancer incidence, such as those related to young-onset CRC, are a reflection 
of both changes in diagnoses (e.g., screening, case ascertainment, practice patterns) and 
exposures (e.g., risk factors). As a result, interpretation of cancer incidence statistics, 
particularly in cancers for which screening may lead to earlier detection, is subject to lead-time 
bias, length-biased sampling, and overdiagnosis.130 Lead time bias and length-biased sampling 
occur when a greater detection of early-stage or slow-growing disease (via screening) artificially 
inflates incidence rates. Overdiagnosis, an extreme form of length-biased sampling, occurs 
when a cancer is detected at such an indolent stage by screening that it would have not been 
diagnosed otherwise. There is often debate over whether increases in cancer incidence are due 
to these biases or represent a true increase in clinically meaningful disease. For example, the 
rise in prostate cancer incidence that followed shortly after in the introduction of prostate-
specific-antigen screening in the late 1980s is believed to be an artifact of earlier diagnoses 
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rather than an increase in disease burden.131 It is important to consider the context and changes 
in diagnostic practices in which increases in incidence may arise.   
Young-onset CRC is a unique opportunity to understand the relationship between 
changes in diagnoses and increases in incidence because of the availability of colonoscopy. 
Screening for CRC with colonoscopy is widely endorsed in older populations to reduce 
incidence and mortality. Although current guidelines recommend average risk individuals begin 
screening at age 50,10 a number of colonoscopies may be performed in younger adults to 
evaluate symptoms related to gastrointestinal diseases (e.g., inflammatory bowel disease). 
More extensive use of colonoscopy in this setting could explain some of the recent increases in 
young-onset CRC; however, the frequency of colonoscopy use in younger populations has not 
been studied.  As a first step toward understanding the impact of colonoscopy on trends in 
incidence, the purpose of this study was to describe patterns of colonoscopy use in a 
commercially insured population of adults under the age of 50. We hypothesized that 
colonoscopy use in younger adults has increased over time but would not fully account for 
trends in the incidence of young-onset CRC 
B. METHODS 
We characterized the patterns of colonoscopy use in younger adults (age <50 years) 
from 2001-2013 using MarketScan Claims and Encounters data (Truven Health Analytics, Ann 
Arbor, MI). MarketScan is a large employer-based claims database that includes 77 contributing 
employers and 12 contributing health plans, with 126 unique carriers and 8 Medicaid states. We 
summed the total number of months that individuals ages 18-49 years were enrolled in their 
insurance plan in each study year. For example, patients who were enrolled in their insurance 
plan for 8 months in the year 2001 (January 1, 2001 to December 31, 2001) contributed 8 
months of “enrollee-time” during that year. Patient enrollee-time was counted in each study year 
without regard to enrollment in previous or subsequent years (i.e., patients could contribute 
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enrollee-time across all calendar years). Using standardized denominators of enrollee-time is a 
reasonable approach because the goal of the analysis was to estimate changes in colonoscopy 
use by year.  
Any colonoscopy delivered in the outpatient setting was identified using International 
Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) and Current 
Procedure Terminology® (CPT) codes. Several validation studies of administrative data support 
the use of ICD-9-CM and CPT codes for identifying colonoscopy procedures.90,91 We described 
time trends in colonoscopy use by calculating the rate of colonoscopy per 1,000 enrollee-years 
in each calendar year. We assumed constant rates within each calendar year. Colonoscopy 
rates were also examined by sex (male vs. female), age group (18-29 years, 30-39 years, 40-49 
years), and geographic region (northeast, north central, west, south). We did not examine the 
indication for colonoscopy because our primary interest was in understanding CRC incidence 
trends (i.e., a colonoscopy would detect cancer regardless of why it was performed). A list of 
ICD-9-CM and CPT codes used to identify colonoscopy is provided in Table 3.4.  
C. RESULTS  
A total of 2,961,283 colonoscopies were performed in 173,774,053 enrollee-years during 
the study period. Mean age (range 35.2-36.5) and number of enrollee-months (range 9.8-10.4) 
contributed by individuals were similar across calendar years. The overall rate of colonoscopy 
increased from 2001 (14.4 per 1,000) to 2009 (18.8 per 1,000) and subsequently decreased 
through 2013 (15.6 per 1,000) (Figure 6.1). Females more frequently received colonoscopy in 
all years compared to males (Figure 6.2). At its peak in 2009, the colonoscopy rate among 
females was 20.6 per 1,000 and 16.6 per 1,000 among males.  Colonoscopy rates were highest 
among the 40-49 year age group and lowest among the 18-29 year age group in all calendar 
years (Figure 6.3). Within each age group, rates generally increased from 2001 to 2009, with 
slight decreases through 2013 (Table 6.1). Colonoscopy rates were similar in the north central 
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and southern regions, but they remained consistently higher in the northeast and lower in the 
west (Figure 6.4) over time.   
D. DISCUSSION  
It is unclear from our findings how the use of colonoscopy in younger populations relates 
to trends in the incidence of young-onset CRC. We expected a more consistent trend in 
colonoscopy rates (i.e., no increase or monotonic increase), but the patterns were variable. The 
use of colonoscopy increased from 2001 through 2009 (relative increase of 30%) and 
accompanied increases in the incidence of CRC in younger populations during that period; 
however, rates of colonoscopy decreased in the latter half of the study period, while CRC 
incidence rates have continued to increase. 
Screening can result in the earlier detection of small tumors that increase incidence and 
survival without changing mortality (i.e., lead-time bias). Early detection should lead to an 
increase in the incidence of early-stage disease that levels off and decreases a few years after 
mass screening is initiated, followed by a decrease in advanced disease. The amount of 
decrease in incidence and the time over which it occurs should reflect how much earlier most 
cancers are being detected. For example, the incidence of CRC in the overall population 
increased shortly after population-based screening was introduced in the 1980s. Incidence rates 
rose from 59.3 per 100,000 in 1975 to 66.3 per 100,000 in 1985.94  Incidence rates have 
subsequently declined (largely due to removing premalignant polyps through polypectomy—see 
Chapter 5). The peak in incidence shows how the introduction of screening technologies can 
initially increase the earlier detection of cancers that may have otherwise been symptomatic in 
later years.  
Increases in cancer incidence may also be a reflection of length-biased sampling 
because screening tests select for cancers that innately possess favorable prognoses. Cancer 
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screening tests work better to identify slower-growing lesions (i.e., those that exist for a longer 
period) than rapidly advancing ones. This is commonly observed in breast cancer, where 
screening (vs. symptomatic) mammography has been shown to be an important prognostic 
factor in survival.132 Like lead-time bias, detection of these incidental or insignificant cancers 
increases the incidence of early-stage cancers and observed survival, but incidence rates 
should slowly level off over time and have no effect on mortality rates or advanced stage 
disease. Both local and regional stage CRC have increased in younger populations2 as 
colonoscopy has become more widespread, which may give the impression that the increases 
in incidence are a reflection of screening-related biases. Mortality rates have remained relatively 
stable.48 However, there is no evidence for the subsequent decline in incidence rates that would 
be expected in the context of these screening biases. Albeit small on the absolute (vs. relative) 
scale, the incidence of young-onset CRC has consistently increased since the 1990s (see 
Chapter 5). The steady increases in incidence, combined with the more variable trends in 
colonoscopy use, may suggest there are factors other than colonoscopy that account for the 
growing number of young patients diagnosed with CRC.  
Despite the ambiguity of its relationship with incidence, we still observed an increase in 
the use of colonoscopy during the first half of the study period (2001-2009). Reasons for this 
increase are difficult to explain. The colonoscopy rates in younger patients parallel a striking rise 
in colonoscopy use among older patients that may have been fueled, in part, by Medicare 
coverage decisions regarding CRC screening. Medicare reimbursement was expanded to 
include screening colonoscopy for those at average-risk in July 2001, largely in an effort to 
reduce access and financial barriers to CRC screening133 (the policy was revised in 2007 so that 
the Part B deductible no longer applied).134 With more widespread use of colonoscopy to screen 
older adults, the thresholds for performing colonoscopy in young patients may have been lower. 
Further, there has been increased recognition of the high profit margins on endoscopy services. 
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Many ambulatory surgery centers were opened in the late 1990s and early 2000s to increase 
the capacity and efficiency of performing colonoscopy. Colonoscopy is the primary revenue 
source for many specialty centers and may account for as much as 60-70% of all revenue.135 
The increased endoscopy capacity may have provided easier access to colonoscopy for 
younger patients.  
In 2010, however, there was a decline in colonoscopy use that persisted through the end 
of the study period. This decline was seen similarly across age, sex, and geographic region.  
One possibility is that the changes in national healthcare policy may have led to stricter 
reimbursement policies. Since it was first introduced in 2010, the Affordable Care Act has 
promoted an increased focus on preserving the quality of care by delivering the right service to 
right patient and right time. All health plans are required to cover preventive services rated as 
grade A or B by the U.S. Preventive Services Task Force (USPSTF), including screening 
colonoscopy, without charging copayment or coinsurance. The USPSTF recommendations 
make clear the appropriate age interval during which routine colonoscopy should be 
performed—between the ages of 50 and 75. Advances in healthcare reform may have 
significantly curtailed the use of endoscopy in populations (including those younger than the 
screening age) where routine use is not recommended.  
Alternatively, the decline in colonoscopy use may be a reflection of the economic 
downturn that followed the 2008 financial crisis. Many Americans lost insurance coverage or 
had reduced benefits as a result of the recession. This was especially true among younger or 
employed populations, where the number of uninsured increased dramatically, and rates of 
employer-sponsored coverage simultaneously declined.136 Downstream effects from the 
economic recession may have impacted willingness to see providers and pay for (expensive) 
colonoscopy copays performed for nonscreening indications. Colonoscopy use did not decrease 
among older persons or those covered under Medicare during this same period. Data from the 
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Behavioral Risk Factor Surveillance System show a comparable proportion (approximately 
65%) of adults up-to-date with CRC screening from 2010-2012.137,138 Similarly, the rates of 
colonoscopy remained relatively constant among adults ages 50-64 in the MarketScan data 
(results not shown). Considered alongside colonoscopy patterns in older adults, declines in 
colonoscopy use among younger populations could be due to the inability to pay for endoscopy 
procedures during a time of economic downturn.  
We also observed differences in colonoscopy use by sex and geographic region, with 
higher rates among females and in the northeast, especially during the period 2001-2009. 
Patterns of colonoscopy overuse among older adults may help explain trends in overuse in 
these two younger population subgroups. Some studies of colonoscopy overuse have found a 
higher proportion of females (vs. males) receive colonoscopy in excess of guideline-
recommended intervals,139 while others show higher rates among males140,141 or no differences 
by sex.142 The exact reasons for the different associations reported in the literature are not fully 
understood. Meanwhile, research139,143 in a wide variety of practice settings, including Medicare, 
the Veterans Health Administration, and integrated care delivery systems, consistently shows 
regional differences in colonoscopy use (for screening or surveillance), with up to 50% variation 
across states.144-146 For example, a study of Medicare patients found substantial geographic 
variation in the frequency of early repeat colonoscopy after a negative screening colonoscopy; 
repeat colonoscopy rates ranged from 40-55%. A similar study among Medicare beneficiaries 
over the age of 70 reports potentially inappropriate colonoscopies that varied from 20-31% by 
health referral region. There was even more variation noted by health service area (i.e., cluster 
of counties that are relatively self-contained with respect to hospital care) within states. 
Geographic variations in care are often due to the availability of medical services rather than 
differences in population health or socioeconomic status.147,148 Further, rates of colonoscopy 
overuse in these studies were generally consistent in groups of contiguous states, which 
suggests local physician practice patterns or supply may drive more frequent use of endoscopy.  
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Separately, our study also highlights the challenges of identifying indication for 
colonoscopy in administrative claims. It has long been recognized that health care data are a 
valuable resource for measuring use, safety, and effectiveness of colonoscopy, but they do no 
not distinguish well between colonoscopies performed for screening and those done for 
surveillance or diagnostic reasons. Differentiating colonoscopies performed to diagnose CRC 
(i.e., a CRC diagnosis is almost always confirmed with colonoscopy) in this population may 
have allowed for a better understanding of how background rates of colonoscopy use 
independently contribute to increases in incidence. A number of algorithms have been 
developed over the past decade or so to improve the classification of colonoscopy indications in 
administrative data.90,91,149-155 Most of these algorithms use diagnosis and procedure codes that 
indicate the presence or absence of gastrointestinal procedures, signs, or symptoms (e.g., 
bleeding). Sensitivity and specificity remain suboptimal, and the algorithms can produce 
different results depending on the codes used or the length of time evaluated prior to the 
colonoscopy. As a result, we did not systematically evaluate the reasons for colonoscopy in this 
younger population. There may be even greater challenges to identifying indications for 
colonoscopy in younger adults because colonoscopies could be billed with symptom-related 
diagnosis codes for the purposes of reimbursement. Regression-based approaches that 
combine electronic health records and billing claims have more recently been used to determine 
colonoscopy indication and show promise for improving the accuracy of existing algorithms.149 
A limitation of this study is the inability to reasonably exclude individuals with a family 
history or genetic predisposition to CRC who would qualify for earlier screening. We also did not 
exclude those with a previous diagnosis of CRC or history of colectomy, but this would be 
infrequent in a younger population. Greater awareness of a family or personal history of CRC—
and the relevant recommendations for screening and surveillance—may have contributed to the 
increases in colonoscopy use we observed. In particular, the higher rates of colonoscopy use 
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among the 40-49 year age group could be due to more conscientious adherence to guidelines 
that advocate earlier screening in higher-risk populations. A recent study156 that examined the 
prevalence of colonoscopy among privately insured (through health maintenance organizations) 
patients aged 40-49 years also found a moderate proportion of patients received screening 
colonoscopy. Consensus guidelines recommend CRC screening for those with a family history 
begin at age 40 or 10 years before the youngest relative was diagnosed with CRC.119 The 
penetrance of genetic mutations (i.e., familial adenomatous polyposis, Lynch syndrome) is 
unlikely to have changed over time,13,14,157 but there may be increased recognition of the 
benefits of earlier screening in higher-risk individuals. In contrast, the increasing number of 
colonoscopies performed in the 18-29 and 30-39 year age groups in this study are not likely to 
be accounted for by family history. The absolute risk of CRC among individuals younger than 
age 40 is very low.  
In addition, we could not quantify the relationship with colonoscopy use and the 
incidence of young-onset CRC. We considered developing a model that estimated the 
association between endoscopy and cancer incidence (i.e., an ecologic analysis that compared 
rates across population subgroups), but we felt substantially limited in identifying a comparable 
population to derive incidence rates. For example, the SEER registries, while widely used in 
studies of cancer incidence, cover a more diverse population with differing levels of insurance 
and healthcare utilization. Persons in MarketScan data are all commercially insured through 
their employers. Our results likely overestimate colonoscopy rates in populations without 
insurance coverage or access to endoscopy. As a result, it would have been difficult to draw 
appropriate conclusions from these two populations together. Further, such a model would 
require multiple assumptions regarding length- and lead-times. Estimates of these parameters 
can vary greatly depending on population and context.158,159 It is unknown whether the 
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assumptions related to lead and length time bias in the overall CRC population are suitable for 
young-onset CRC.  
There are several strengths of this study. Colonoscopy is considered to be well-reported 
in claims because it is an expensive procedure. We used procedure codes that have been 
shown to accurately identify colonoscopy in outpatient settings. In addition, we used a large, 
employer-based claims database, which yielded a large enough study population to determine 
the use of a relatively uncommon procedure (i.e., the prevalence of colonoscopy in younger 
individuals is low). Although individuals represented in MarketScan are all insured through their 
employers, and findings cannot be generalized to uninsured populations or those without 
access to endoscopy, the data do have a number of advantages. MarketScan is fully integrated 
(inpatient, outpatient, enrollment) at the patient-level, represents all ages (i.e., compared to 
Medicare claims that generally only cover age ≥65), and is not limited to a single payor or 
geographic region.   
Little is known about the underlying mechanisms and factors that have contributed to 
increases in CRC incidence in younger populations. The trends in colonoscopy use we 
observed among younger adults were similar to those in age-eligible (i.e., age ≥50 years) 
populations reported by others, where the use of colonoscopy for CRC screening and the use of 
any lower endoscopy (regardless of screening indication) have both increased since 2000. 
Although colonoscopy use in younger adults has increased, the declines in in more recent years 
could suggest there are other factors—beyond those related to detection and diagnosis—
involved in the development of young-onset CRC. 
 
  
 
 
Table 6.1:Number of colonoscopies performed (in thousands), enrollee-years (in thousands), and colonoscopy rate per 1,000 
enrollee-years, overall and by sex, age, and geographic region 
  
 Calendar Year 
 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 
Overall              
COL 35.4 71.5 110.7 157.9 180.6 210.3 210.8 320.9 315.1 330.5 364.9 365.7 287.1 
Enrollee-Years 2,458.2 4,754.3 7,321.8 9,525.5 10,535.3 12,019.3 11,918.3 17,176.6 16,802.1 18,860.7 21,717.0 22,308.6 18,376.3 
Rate 14.4 15.0 15.1 16.6 17.1 17.5 17.7 18.7 18.8 17.5 16.8 16.4 15.6 
              
Male              
COL 14.9 29.3 46.1 65.8 75.5 87.7 88.0 136.2 132.4 137.7 153.3 153.1 119.1 
Enrollee-Years 1,146.2 2,219.3 3,429.9 4,463.3 4,953.6 5,732.0 5,686.0 8,167.2 7,954.2 8,998.8 10,466.9 10,815.3 8,839.0 
Rate 13.0 13.2 13.5 14.7 15.3 15.3 15.5 16.7 16.6 15.3 14.6 14.2 13.5 
Female              
COL 20.5 42.2 64.6 92.1 105.0 122.6 122.8 184.7 182.7 192.7 211.5 212.6 168.1 
Enrollee-Years 1,312.0 2,535.0 3,891.9 5,062.2 5,581.8 6,287.3 6,232.3 9,009.4 8,847.9 9,861.9 11,250.2 11,493.3 9,537.3 
Rate 15.6 16.7 16.6 18.2 18.8 19.5 19.7 20.5 20.6 19.5 18.8 18.5 17.6 
              
18-29 Years              
COL 3.0 6.9 10.7 16.3 19.0 23.1 24.2 38.8 39.9 42.3 52.8 55.8 43.7 
Enrollee-Years 732.1 1,443.7 2,170.8 2,840.0 3,156.8 3,680.2 3,718.3 5,442.7 5,339.3 5,927.0 7,405.5 7,884.1 6,607.7 
Rate 4.1 4.7 5.0 5.7 6.0 6.3 6.5 7.1 7.5 7.1 7.1 7.1 6.6 
30-39 Years              
COL 7.6 16.5 25.3 36.2 41.2 48.6 48.9 75.6 75.3 79.6 86.5 87.9 68.2 
Enrollee-Years 733.8 1,495.0 2,330.3 2,985.3 3,296.1 3,736.8 3,692.9 5,350.1 5,243.4 5,918.5 6,521.0 6,603.8 5,408.1 
Rate 10.4 11.0 10.9 12.1 12.5 13.0 13.2 14.1 14.4 13.5 13.3 13.3 12.6 
40-49 Years              
COL 24.8 48.2 74.7 105.5 120.4 138.6 137.7 206.4 199.9 208.5 225.6 222.0 175.2 
Enrollee-Years 992.3 1,815.5 2,820.7 3,700.2 4,082.5 4,602.3 4,507.1 6,383.8 6,219.3 7,015.3 7,790.5 7,820.8 6,360.5 
Rate 25.0 26.5 26.5 28.5 29.5 30.1 30.6 32.3 32.1 29.7 29.0 28.4 27.5 
              
Northeast              
COL 5.6 8.1 13.6 17.4 20.6 23.9 21.6 58.8 48.5 60.4 79.3 79.2 65.8 
Enrollee-Years 338.7 445.4 684.7 821.3 1,000.1 1,135.6 1,026.3 2,694.6 2,193.7 2,856.2 3,883.7 3,971.9 3,436.1 
Rate 16.4 18.3 19.9 21.2 20.6 21.0 21.1 21.8 22.1 21.1 20.4 19.9 19.2 
North Central              
COL 10.9 19.8 25.2 32.5 38.3 60.5 59.8 79.0 81.9 81.7 85.4 85.6 60.0 
Enrollee-Years 686.6 1,219.3 1,493.1 1,875.9 2,112.5 3,335.7 3,291.7 4,222.0 4,350.7 4,570.8 5,045.6 5,143.8 3,833.8 
Rate 15.9 16.3 16.9 17.3 18.1 18.1 18.2 18.7 18.8 17.9 16.9 16.6 15.7 
West              
COL 15.2 35.1 48.8 78.8 89.7 99.8 102.7 147.6 147.9 137.9 139.5 137.1 104.5 
Enrollee-Years 983.6 2,238.4 2,903.0 4,312.0 4,785.0 5,619.3 5,648.3 7,696.4 7,671.6 7,519.7 7,987.3 8,148.7 6,346.5 
Rate 15.5 15.7 16.8 18.3 18.7 17.8 18.2 19.2 19.3 18.3 17.5 16.8 16.5 
9
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South              
COL 3.7 8.2 22.3 27.1 30.2 24.4 25.7 34.4 36.1 47.5 49.2 55.4 48.6 
Enrollee-Years 445.9 838.1 2,182.2 2,396.6 2,534.6 1,839.7 1,901.1 2,490.3 2,531.6 3,838.3 4,125.2 4,597.7 4,290.6 
Rate 8.2 9.8 10.2 11.3 11.9 13.2 13.5 13.8 14.3 12.4 11.9 12.0 11.3 
NOTE: Colonoscopy rate reported as number of colonoscopies performed per 1,000 enrollee-years 
Abbreviations: COL, colonoscopies 
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Figure 6.1. Colonoscopy rate per 1,000 enrollee-years by calendar year
  
 
 
  
Calendar Year 
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Figure 6.2. Colonoscopy rate per 1,000 enrollee-years by calendar year and sex
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Figure 6.3. Colonoscopy rate per 1,000 enrollee years by calendar year and age 
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Figure 6.4. Colonoscopy rate per 1,000 enrollee years by calendar year and geographic region
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CHAPTER 7 
DISCUSSION 
 
A. SUMMARY OF FINDINGS 
This dissertation examined the increasing incidence of colorectal cancer (CRC) in 
younger (age <50 years) adults by leveraging large, population-based data sources. There were 
three primary goals: 1) to describe the demographic, clinicopathologic, and socioeconomic 
characteristics (Specific Aim 1a) and treatment patterns (Specific Aim 1b) of younger patients 
newly diagnosed with stages II and II CRC; 2) to estimate the contribution of age, time period, 
and birth cohort to increases in the incidence of young-onset CRC (Specific Aim 2a) and 
describe difference in the prevalence of lifestyle-related behavior risk factors by time period and 
birth cohort (Specific Aim 2b); and 3) to determine patterns of colonoscopy use in younger 
adults (Specific Aim 3).  
To accomplish the first aim, Patterns of Care (POC) studies were used to compare the 
demographic, clinicopathologic, and socioeconomic characteristics of younger and older 
patients newly diagnosed with stages II and III CRC. POC data were linked with the Area Health 
Resource File (AHRF) to better describe socioeconomic indicators of the study population. 
Differences in treatment patterns (e.g., surgery, chemotherapy, and radiation therapy) were also 
examined across categories of age at diagnosis. Receipt of chemotherapy and radiation therapy 
was verified by the treating physician.  Results showed important differences in the distribution 
of young-onset CRC by race/ethnicity. A higher proportion of black (13%) and Hispanic (15%) 
patients were diagnosed at age <50 years compared to whites. Young black patients more 
frequently had tumors located within the proximal colon (39%), whereas a higher proportion of 
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young white (41%) and Hispanic (33%) patients had rectal tumors. Combined with the growing 
literature on CRC tumor subtypes (i.e., showing differences in tumor subtypes by race), the 
differences we observed by race/ethnicity provide additional evidence for distinct mechanisms 
that may be driving CRC progression across population subgroups. In addition, younger CRC 
patients more frequently received “optimal” care, including better nodal counts at surgery, 
treatment at academic medical centers, and chemotherapy and radiation therapy. This may be a 
reflection of physician preferences to ambitiously treat disease simply based on younger age at 
presentation.  
The second aim used Hierarchical Poisson models to estimate the independent effects 
of age, time period, and birth cohort on incidence of CRC. Incidence rates for all stages of CRC 
were derived from the Surveillance, Epidemiology, and End Results (SEER) program of cancer 
registries. When considered alongside Specific Aim 1, the findings from this aim give additional 
support to the hypothesis that there may be different mechanisms involved in the development 
of CRC across the life course. Specially, there was a differential contribution of time period and 
birth cohort on incidence patterns by age. Both a period (σ=0.02, p=0.02) and cohort (σ=0.04, 
p=0.004) effect were observed in the incidence of CRC in older (age ≥50 years) populations, but 
in contrast, there was only a cohort (σ=0.01, p=0.04) effect on young-onset CRC. In addition, 
the results show small absolute (vs. relative) increases in the incidence of young-onset CRC 
over time. Incidence rates increased by only a few additional cases per 100,000 persons over a 
40-year time period, while others have simultaneously suggested relative increases of over 
100%. Rather, the most dramatic changes in incidence occurred in the screening-age (≥50 
years) population, with large declines in incidence from the earliest to most recent time period. 
Some professional organizations have promoted changing screening guidelines to being 
average-risk screening at a younger age, but these findings highlight the importance of 
evaluating absolute measures when making public health policy decisions.      
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As part of the second aim, trends in the prevalence of obesity, physical inactivity, and 
smoking were also examined across time period and birth cohort using data from the National 
Health and Nutrition Examination Survey (NHANES), Behavioral Risk Factor Surveillance 
System (BRFSS), and National Health Interview Survey (NHIS), respectively. The prevalence of 
obesity generally increased across time period (12.9% in 1975-79 to 34.6% in 2010-12) and 
birth cohorts (18.3% in 1924-29 to 27.6% in 1985-91), with the largest increases among black 
females. Physical inactivity remained relatively stable over time (21.1% in 1985-89 to 20.1% in 
2010-12) in all race/sex subgroups combined. Trends in cohort-physical inactivity were more 
consistent, with general declines across successive birth cohorts (29.9% in 1940-44 to 17.6% in 
1980-84). The prevalence of smoking decreased dramatically across time periods (43.5% in 
1974-74 to 24.8% in 2010-12) and birth cohorts (42.0% in 1924-29 to 26.0% in 1985-91), 
although there were some modest increases in smoking behavior among white males in the 
most recent birth cohorts. Population surveys can be helpful in efforts to understand the context 
of incidence trends, but they do not provide the level of detail needed to identify risk factors for 
disease. The results underscore the need for a better understanding of the risk factors, 
particularly those that may be related to differences across birth cohort, involved in the 
development of young-onset CRC. 
Finally, in the third aim, patterns of colonoscopy use in younger adults (age <50 years) 
were examined in MarketScan Claims and Encounters data. MarketScan is a large employer-
based administrative claims database that includes 77 contributing employers and 12 
contributing health plans. Any colonoscopy performed in the outpatient setting was identified 
using validated procedure codes. Time trends in colonoscopy were described by calculating a 
rate of colonoscopy per 1,000 enrollee-years in each calendar year. The overall rate of 
colonoscopy increased from 2001 (14.4 per 1,000) to 2009 (18.8 per 1,000) and subsequently 
decreased through 2013 (15.6 per 1,000). Colonoscopy rates were highest in females, 
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individuals aged 40-49 years, and the northeast. These results provide some evidence that the 
wider use of colonoscopy in younger populations may partially explain rises in the incidence of 
young-onset CRC. However, rates of colonoscopy decreased in the latter half of the study 
period, while CRC incidence rates in younger populations have continued to increase. The more 
recent decline in colonoscopy use may suggest increases in young-onset CRC cannot be solely 
attributed to changes in the detection and diagnosis of CRC (via colonoscopy) but could also be 
related to changes in risk factors, such as obesity, over time.   
B. PUBLIC HEALTH IMPLICATIONS 
 The results of this dissertation research have several implications for public health and 
clinical practice. First, this research enhances our understanding of the factors involved in the 
development of young-onset CRC and provides a real world context for understanding age-
related differences in CRC incidence. Given the decreases in CRC incidence in older 
populations (i.e., due to screening), the findings show the age distribution of CRC is changing. 
Others have similarly noted that nearly 1 in 7 patients diagnosed with CRC is under the age of 
50.160 Despite the overall population trends in aging, by 2030, approximately 11% of all colon 
and 23% of all rectal cancers may be diagnosed in younger patients.68 Although the increases 
are small in absolute magnitude, changes in the age distribution of CRC point to the challenges 
of managing CRC in younger patients, including earlier recognition of symptoms at diagnosis 
and treatment approaches. Younger patients may also experience problems with fertility, 
employment and productivity loss, and long-lasting treatment sequelae.   
This work also highlights differences in CRC by race/ethnicity. Racial disparities in CRC 
incidence and mortality have long been recognized; blacks continually experience higher 
incidence and mortality rates compared to whites. Racial differences in CRC incidence may be 
a reflection of differences in the uptake of CRC screening among whites and blacks. NHIS data 
have historically shown substantially lower screening rates in blacks than whites,66 although 
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more recent evidence from BRFSS suggests screening rates have become comparable 
(~58%).161 It may be that differences in follow-up of abnormal screenings or use of surveillance 
screening, which are not captured by population-based surveys, also account for disparities in 
incidence and stage. Another possibility is that blacks are more frequently screened with fecal 
occult blood testing (FOBT),162 while a higher proportion of whites undergo colonoscopy, and 
the effectiveness of FOBT may be reduced when patients do not adhere to a regular 
schedule.163-166 Our findings support efforts to target screening programs in the underserved or 
interventions 
Others have noted racial differences in tumor subsite, which was also observed in our 
Specific Aim 1. These differences may be a reflection of differences in biology or CRC risk 
factors (e.g., higher prevalence of obesity, physical activity levels, and cultural differences in 
diet) rather than disparities in detection and treatment. However, little scientific progress has 
been made in improving our understanding of the biological differences that contribute to the 
distribution of CRC tumor subtypes by race.  
Lastly, this work has implications for the national program of CRC screening. Population-
based cancer screening is often cited as an important success of the public health system in the 
U.S. CRC screening was first introduced in the late 1980s when the National Cancer Institute 
developed working guidelines for the early detection of cancer and is currently recommended at 
age 50 for those at average-risk. Given the increases in young-onset CRC, some have argued 
in favor of changing screening guidelines to being average-risk screening at a younger age, 
such as age 40. The findings of this study, however, highlight the importance of considering 
absolute (vs. relative) measures when making public health policy decisions. Although incidence 
of young-onset CRC has increased, the absolute incidence rates have only increased by a few 
cases per 100,000 persons over a 40-year time period. Screening decisions should be based on 
the balance of risks and benefits and not solely on increases in incidence.  
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C. STRENGTHS 
Research Guided by Conceptual Framework 
 This dissertation addressed several gaps in our understanding of young-onset CRC. 
Most studies have failed to consider the multiple influences that have likely contributed to the 
increase in CRC incidence among younger adults, instead only focusing on a single dimension 
of CRC (e.g., relative increases in incidence). We relied on a conceptual model to leverage 
complementary methods from the fields of epidemiology, demography, and health services use 
to examine the underlying mechanism that have led to increases in CRC incidence in younger 
populations.  
Population-Based Data Sources (Specific Aims 1 and 2) 
An important strength of this study is the use of several population-based data sources 
(POC, SEER, BRFSS, NHIS, NHANES). Previous research has been limited to single institution 
studies or relied on small sample sizes, in which results generally reflect the distribution of 
characteristics of CRC patients treated at that institution rather than true characteristics of 
young-onset CRC. The breadth of data used in this study, ranging from a population-based 
cancer registry to national surveys on health behaviors, provided a robust, real world context for 
examining the increasing incidence of CRC in younger populations. For example, data from 
POC studies offer a number of unique advantages for conducting population-based 
epidemiologic research because each participating SEER registry area has a defined 
population. The age and sex distributions of patients in POC reflect those of the U.S. population, 
and the SEER program includes registries with a higher percentage of African Americans 
(Detroit, Atlanta, Louisiana), Asians (Seattle, San Francisco, Los Angeles, San Jose-Monterey), 
and Hispanics (Los Angeles, Greater California, New Mexico). The large size and ethnic 
diversity of these data sources were also strengths that enabled us to examine differences 
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within population subgroups by race/ethnicity. The study findings are generalizable because the 
demographic profiles of patients include in this study are similar to that of the general U.S. 
population.  
Physician Verification of Treatment Receipt (Specific Aim 1) 
 POC studies also provide a greater breadth and depth of information than that available 
solely from medical claims and/or SEER registries. This was particularly true for our assessment 
of receipt of chemotherapy and radiation therapy in Specific Aim 1b. Detailed tumor and 
treatment information was abstracted from patient medical records and verified by treatment 
physicians; doctor verification substantially improved the completeness of treatment 
ascertainment (or confirmed that no chemotherapy or radiation therapy were given).   
Measurement of Colonoscopy (Specific Aim 3) 
 Lastly, a strength of the study was measurement of colonoscopy in Specific Aim 3 in 
MarketScan data. Marketscan is fully integrated (inpatient, outpatient, enrollment) at the patient-
level, represents all ages (i.e., compared to Medicare claims that generally only cover age ≥65), 
and is not limited to a single payor or geographic region. Colonoscopy is considered to be well-
reported in administrative claims because it is an expensive procedure. We used procedure 
codes that have been shown to accurately identify colonoscopy performed in outpatient settings. 
In addition, we used a large employer-based claims database, which yielded a large enough 
study population to determine the use of a relatively uncommon procedure (i.e., prevalence of 
colonoscopy in younger adults is low). 
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D. LIMITATIONS 
Unknown Family History of or Genetic Predisposition to CRC (Specific Aims 1 and 3) 
 A limitation of the study was the inability to exclude persons with a family history of or 
genetic predisposition to CRC. Although the prevalence of these syndromes in younger 
populations remains very low,13,14 the data may have helped explain changes in the distribution 
of young-onset CRC we observed in Specific Aim 1. In addition, higher-risk individuals would 
quality for earlier screening. Greater awareness of a family history or personal history of CRC—
and the relevant recommendations for screening and surveillance—may have contributed to the 
increases in colonoscopy use we observed in Specific Aim 3. The higher rates of colonoscopy 
use among the 40-49 year age group could be due to more conscientious adherence to 
guidelines that advocate earlier screening in higher-risk populations. The penetrance of genetic 
mutations is unlikely to have changed over time, but there may be increased recognition of the 
benefits of earlier screening in higher-risk persons.  
Information on Molecular Markers Not Routinely Collected (Specific Aim 1) 
We also lacked data on molecular markers of CRC that may have helped explain the 
results of Specific Aim 1 on differences in young-onset CRC by race/ethnicity. There is growing 
recognition that CRC is a heterogeneous disease, often defined by combinations of DNA 
mismatch repair or microsatellite instability (MSI), MLHI methylation (i.e.,CpG island methylator 
phenoypte), and mutations in BRAF and KRAS oncogenes. However, few patients in POC 
studies received MSI testing, and even fewer received KRAS and BRAF testing (data not 
shown), which precluded our ability to report the prevalence of molecular markers in the study 
population. These data may have supported the differences in tumor subtypes across racial 
groups reported in other studies. Collection efforts have likely improved since the study period 
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(1990-2010), and SEER now includes site-specific factors on MSI and KRAS mutation. Our 
study highlights the continued need for robust sources of molecular data at the population-level.  
Ecologic Analysis of CRC Risk Factors (Specific Aim 2) 
Our analysis of CRC risk factors in Specific Aim 2 was limited to aggregate measures of 
obesity, physical inactivity, and smoking. Population surveys can be helpful in efforts to 
understand the context of incidence trends, but they do not provide the level of detail needed to 
identify risk factors for the disease. Ecological data describes characteristics of a group, and 
conclusions cannot be made regarding individuals (i.e., ecologic fallacy). Further, the APC 
models used in our study are not models of etiology and cannot provide information on the 
specific mechanism by which these risk factors are related to carcinogenesis. The analysis does 
not distinguish between the many factors that have led to increases in obesity prevalence (e.g., 
diet) that could also be related to CRC risk. There may be other etiologic factors or exposures 
that could not be accounted for in this study (e.g., intestinal microbiota), either because their 
relationship with CRC risk is still unknown or the prevalence is not monitored in population-
based sources with sufficiently long follow-up.  
Synthetic Cohort Approach (Specific Aim 2) 
We used a synthetic cohort approach in Specific Aim 2 to estimate the effect of birth 
cohort on CRC incidence rates. Specifically, by pooling SEER incidence data, we created a 
rectangular age by period array where columns corresponded to age-specific incidence rates in 
each period, and rows were age-specific incidence rates across all periods (see Figure 3.3). 
Linking the diagonal cells of the array gave incidence rates that belonged to individuals born in 
the same calendar year and age together (i.e., birth cohort). Although this approach is often 
used in demographic research, only a longitudinal panel study design provides data from true 
birth cohorts that follow identical individuals over time. As a result, we lacked data at the tail 
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ends (i.e., in the earliest and most recent cohorts) because not all ages were equally 
represented across the study period. This was also true for birth cohort patterns of lifestyle-
related risk factors that were derived from NHANES, BRFSS, and NHIS.   
Generalizability of Results from MarketScan (Specific Aim 3) 
Colonoscopy rates were estimated using data from MarketScan. Although MarketScan 
provides a number of advantages over other administrative claims, individuals are all insured 
through their employers, and findings cannot be generalized to uninsured populations or those 
without access to endoscopy. The results may overestimate colonoscopy rates in the general 
population, where a greater proportion of younger adults may lack insurance coverage for the 
procedure. In addition, because colonoscopy is predominantly performed for screening in older 
adults, much of the literature on patterns of colonoscopy use is focused on the Medicare 
population. This made it challenging to draw comparisons to our results and provide 
explanations for variations in colonoscopy use in younger adults.    
E. FUTURE RESEARCH 
There are two important areas of future research that may build upon these results and 
address the limitations described above. First, results from Specific Aim 1 highlight the need for 
a better understanding of the differences in molecular markers of CRC (e.g., MSI and BRAF and 
KRAS mutations) by age and race/ethnicity. Research has only recently explored the molecular 
features of young-onset CRC and found no difference in the overall mutational rate among 
younger and older patients. However, the specific mutations involved in young-onset CRC 
appear to be distinct. An emerging body of literature also shows there differences in CRC tumor 
subtypes across racial groups. For example, KRAS mutations are more common in black 
patients, while the frequency of BRAF mutation tends to be higher in tumors from whites. There 
are likely distinct mechanism driving CRC progression in various population subgroups. 
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Population-based studies (vs. those done in single institution settings) of molecular differences 
in young- and older-onset CRC may identify pathways of CRC carcinogenesis that account for 
the growing number of young patients diagnosed with CRC.   
In addition, these results leave room for a more critical analysis of the risk factors for 
young-onset CRC. For example, the analysis of NHANES data shows increases in the 
prevalence of obesity in younger populations across both time periods and birth cohorts. It may 
be that increases in central adiposity, especially at younger ages, account for some of the 
increases in incidence, but the mechanisms involved in obesity and cancer risk have not been 
fully elucidated. The findings related to trends in obesity, physical inactivity, and smoking point 
to additional factors that may increase risk of young-onset CRC. Increases in incidence in 
younger persons reflect changes in that population and may be a reasonable focus for future 
etiologic studies 
F. CONCLUSIONS 
This study provides strong support for differences in the etiology of CRC across the life 
course. There may be different mechanisms involved in the development of CRC in younger 
(vs. older) adults. Specifically, results from Specific Aim 1 show differences in the distribution of 
CRC by age, race/ethnicity, and tumor subsite, and Specific Aim 2 demonstrates age-related 
differences in the effect of time period and birth cohort on incidence patterns. The mechanisms 
responsible for increases in young-onset CRC, albeit small on an absolute scale, remain 
unknown. Collectively, the results of this dissertation work underscore the need for a better 
understanding of the critical factors involved in the onset of CRC by age and race/ethnicity.  
 
 
 
 
APPENDIX A: FACTORS ASSOCIATED WITH YOUNG-ONSET COLORECTAL CANCER IN STUDIES WITH A COMPARISON 
GROUP 
 Author (year) 
  
Chiang 
(2003) 
Chou 
(2011) 
Ganapathi 
(2011) 
Griffen 
(1991) 
Karsten 
(2008) 
Li      
(2011) 
Liang 
(2002) 
Marble 
(1992) 
Mitry 
(2000) 
O'Connell 
(2004) 
Paraf1 
(2000) 
Parramore 
(1998) 
Quah 
(2007) 
Savas 
(2007) 
Schellerer 
(2012) 
Wang 
(2010) 
Yantiss 
(2009) 
You2 
(2011) 
Sociodemographic 
Characteristics 
                  
Race/Ethnicity3 
   + +    *  +  +    +   
Female Sex 
* +    * * *  + * -  - * - * * 
Family History4 
    +  * *   +  *    *  
Symptoms at 
Diagnosis 
                  
Rectal Bleeding 
 *   *   *           
Abdominal Pain 
 +   *   *           
Change in bowel 
Habits  *   *              
Weight Loss 
 +   *              
Constipation  
 *                 
Diarrhea  
 *                 
Nausea/ Vomiting 
 *                 
Bowel Obstruction  
    *        *      
Tenesmus  
 *                 
Bloating 
 *                 
Poor Performance 
Status5               +    
History of Crohn's 
Disease/ Ulce. Colitis         *          
Clinicopathologic 
Characteristics 
                  
Higher Stage at 
Diagnosis                   
Tumor Site 
* * * * 
+ 
 (right) * * 
+ 
(right) 
+  
(left)  * 
+  
(rectum) 
+  
(left) 
+ 
 (right) 
+  
(rectum)  
+ 
(rectum)  
Larger Tumor Size 
     * *          * * 
Poorly/ Undifferent. 
Grade 
+ + + + + * + +  + * + *  *  * * 
1
1
2
 
 
 
 Author (year) 
  
Chiang 
(2003) 
Chou 
(2011) 
Ganapathi 
(2011) 
Griffen 
(1991) 
Karsten 
(2008) 
Li      
(2011) 
Liang 
(2002) 
Marble 
(1992) 
Mitry 
(2000) 
O'Connell 
(2004) 
Paraf1 
(2000) 
Parramore 
(1998) 
Quah 
(2007) 
Savas 
(2007) 
Schellerer 
(2012) 
Wang 
(2010) 
Yantiss 
(2009) 
You2 
(2011) 
Lymphovas. Invasion 
 * +  * * *    *  *  *  +  
Perineural Invasion  +   *      *  *  *    
Venus Invasion               *  +  
Infiltrative Tumor 
Growth Pattern            *        
Gross Type 
(Ulcerative vs. 
Polypoid)      * *            
PNCA6 Count 
          *        
Lymphocyte 
Infiltration       *            
Synchronous Tumor 
 *     +      *      
Peritoneal Metastasis 
              *    
CEA 
     * *            
MMP-2 
     *             
P27 KIP1 
     *             
EGFR 
                *  
P53 
      -          *  
BRAF Mutation 
                *  
KRAS Mutation 
      *          *  
Microsatellite 
Instability       +            
Treatment 
                  
Surgery  
    *    + *         
Emergent Surgery  
 * +            -    
Total Colectomy 
 *           *     + (APR) 
Resection Status 
        *    *  *    
Greater Number of 
Lymph Nodes 
Sampled  + +          +   +   
Surgical Mortality 
 *     +  +      +    
Surgical Morbidity 
              +    
Chemotherapy  
 +       +    +  +   + 
1
1
3
 
 
 
 Author (year) 
  
Chiang 
(2003) 
Chou 
(2011) 
Ganapathi 
(2011) 
Griffen 
(1991) 
Karsten 
(2008) 
Li      
(2011) 
Liang 
(2002) 
Marble 
(1992) 
Mitry 
(2000) 
O'Connell 
(2004) 
Paraf1 
(2000) 
Parramore 
(1998) 
Quah 
(2007) 
Savas 
(2007) 
Schellerer 
(2012) 
Wang 
(2010) 
Yantiss 
(2009) 
You2 
(2011) 
Radiation  
        + +        + 
Survival 
                  
Overall Survival 
 * * * *   - *  * * *  + +   
Disease-Free Survival 
 - *   *       *     * 
Cancer-Specific 
Survival  -     *      *  * *  * 
Recurrence7 
                                  + 
NOTE: *, no association; +, positive association; -, negative association 
1Paraf (2000) was a case-control study matched on sex, stage at diagnosis, and tumor site 
2You (2011) was limited to rectal cancer only 
3In all studies except Karsten (2008), black race was associated with early-onset CRC. In Karsten (2008), Hispanic and Asian race/ethnicity were positively 
associated 
4Family history does not include Familial Adenomatous Polyposis (FAP) or Lynch Syndrome 
5Performance status measured by American Society of Anesthesiologists (ASA) physical status classification system 
6PCNA, proliferative cell nuclear antigen 
7No recurrence or only distant recurrence more common in younger patients 
 
 
 
  
1
1
4
 
 
 
APPENDIX B: CHARACTERISTICS OF PATIENTS WITH YOUNG-ONSET COLORECTAL CANCER IN STUDIES WITH NO 
COMPARISON GROUP 
Author 
(year) 
Study 
Population 
Race Sex Age 
Symptoms at 
Diagnosis 
Family History 
Stage at 
Diagnosis 
Tumor Site Histology Tumor Grade Overall Survival 
Cusack 
(1996) 
186 patients 
age ≤ 40 years 
treated for 
primary 
colorectal 
adenocarcinom
a 1961-1990; 
MD Anderson 
Cancer Center 
75.8% 
white, 
15.6% 
black, 7.5% 
Hispanic, 
1.1% Asian 
48.9% male, 
51.1% 
female 
34.3 
(median), 
range 14-40 
Abdominal pain 
(30.5%), rectal 
bleeding (43.7%), 
back pain (2.3%), 
nausea/vomiting 
(2.9%), weight loss 
(1.7%), bowel 
obstruction (5.2%) 
2 (1.1%) FAP, 
4 (2.2%) 
HNPCC  
8.1% stage I, 
26.3% stage II, 
31.7% stage III, 
33.9% stage IV 
41.6% rectum, 
21.1% sigmoid 
colon, 9.3% left 
colon, 10.3% 
transverse colon, 
15.7% right colon, 
2.2% multiple sites 
78.6% intestinal 
type 
adenocarcinoma, 
10.3% mucinous 
adenocarcinoma, 
11.1% signet ring 
cell 
12.3% well-
differentiated, 
46.7% 
moderately 
differentiated, 
40.9% poorly 
differentiated 
43% (5-year OS), 
35 months 
(median survival 
time) 
Dozois 
(2008) 
1025 patients 
age ≤ 50 years 
diagnosed with 
primary CRC 
1976-2002; no 
history of FAP, 
HNPCC, or 
IBD; Mayo 
Clinic 
 
57.1% male, 
42.9% 
female 
42.4 (mean), 
st dev 6.4  
Rectal bleeding 
(50.7%), abdominal 
pain (32.5%), 
change in bowel 
habits (18.0%), 
diarrhea (13.2%), 
rectal pain (7.0%), 
bloating (7.3%), 
constipation (8.4%), 
weight loss (13.2%), 
nausea/vomiting 
(6.6%) 
181 (17.7%) 
first-degree 
relative with 
CRC, 79 (7.7%) 
second-degree 
relative with 
CRC 
13.4% stage I, 
20.4% stage II, 
32.1% stage III, 
34.0% stage IV 
49.1% rectum, 
29.1% left colon, 
21.9% right colon  
11% mucinous 
adenocarcinoma, 
2% signet ring 
cell 
2.0% grade I, 
53.6% grade 2, 
34.0% grade 3, 
7.2% grade 4, 
2.9% unknown 
grade 
 
Fancher 
(2011)1 
45 patients age 
≤ 50 years 
underwent 
CRC surgery 
1998-2007; no 
history of FAP 
or UC; 
Waterbury, CT 
66.7% 
white,  
33.3% 
black 
43% male, 
57% female 
43.6 (mean)  
17 (37.8%) with 
family history of 
CRC (not 
defined) 
31.9% stage I, 
17.0% stage II, 
23.4% stage III, 
27.7% stage IV 
53.3% left colon, 
48.9% right colon 
  
28.6 months 
(mean survival 
time) 
Lee (1994) 
62 patients age 
≤ 40 years 
diagnosed with 
CRC 1968-
1991; Oregon 
Health Science 
University/ 
Portland VA 
  
34.5 (mean) 
range 18-40  
Pain (78%), 
bleeding (70%), 
weight loss >10 lbs 
(53%), obstruction 
(26%), perforation 
(5%) 
5 (8%) FAP 
8% Dukes A, 
20% Dukes B, 
23% Dukes C, 
48% Dukes D 
28% right colon, 
14% transverse 
colon, 21% left 
colon, 26% 
rectum, 9% 
multiple sites 
22.6% mucinous 
adenocarcinoma 
 
67.8% (5-year 
OS); by stage, 5-
year OS 100% 
Dukes A, 85% 
Dukes B, 40% 
Dukes C, 7% 
Dukes D 
1
1
5
 
 
 
Author 
(year) 
Study 
Population 
Race Sex Age 
Symptoms at 
Diagnosis 
Family History 
Stage at 
Diagnosis 
Tumor Site Histology Tumor Grade Overall Survival 
Leff (2007) 
49 patients age 
≤ 40 years 
diagnosed with 
CRC 1982-
1992; United 
Kingdom 
 
57% male, 
43% female 
32 (mean) 
Rectal bleeding 
(69%), change in 
bowel habits (51%), 
abdominal pain 
(34%), weight loss 
(8%), anemia (8%) 
2 (4%) FAP; 2 
(4%) first-
degree relative 
with CRC 
14% Dukes A, 
24% Dukes B, 
44% Dukes C, 
16% Dukes D 
65% rectum, 12% 
right colon, 4% 
transverse colon, 
2% left colon, 16% 
sigmoid colon 
 
12% well-
differentiated, 
59.1% 
moderately 
differentiated, 
22% poorly 
differentiated 
58% (5-year OS), 
46% (10-year OS) 
Lin (2005) 
45 patients age 
≤ 39 years 
diagnosed with 
CRC 1992-
2002; Taipei 
 
49% male, 
51% female 
32 (mean), 
range 18-39 
Abdominal pain 
(53%), bloody 
stools (24%), 
change in bowel 
habits (13%), 
protruding mass 
(6%), obstruction 
(2%) 
2 (4.4%) first-
degree and 
second-degree 
relatives with 
CRC 
11.1% Dukes B, 
24.4% Dukes C, 
66.7% Dukes D 
36% right colon, 
23% left colon, 
24% rectosigmoid, 
17% transverse 
colon 
24% mucinous 
adenocarcinoma, 
76% typical 
adenocarcinoma 
49% well-
differentiated, 
25% poorly 
differentiated 
34% (2-year OS), 
9% (5-year OS) 
MacGillivray 
(1991) 
50 patients age 
≤ 39 years 
diagnosed with 
CRC 1962-
1988; National 
Naval Medical 
Center 
 
66% male, 
34% female 
20 (mean), 
30.5 
(median), 
range 19-39 
Rectal bleeding 
(54%), abdominal 
pain (44%), change 
in bowel pattern 
(16%), weight loss 
(16%) 
1 (2%) HNPCC; 
8 (16%) family 
history (not 
defined) 
4% Dukes A, 
26% Dukes B, 
42% Dukes C, 
24% Duke D 
36% rectum, 2% 
transverse colon, 
31% right colon, 
31% left colon 
  
43% (5-year OS), 
35% (10-year OS), 
28 months 
(median survival 
time) 
Makela 
(2010) 
59 patients age 
≤ 40 years 
diagnosed with 
CRC 1984-
2003; Oulu, 
Finland 
 
49.2% male, 
50.8% 
female 
36 (mean), 
range 23-40 
Rectal bleeding, 
change in bowel 
habits, abdominal 
pain, obstruction 
(no prevalence 
given) 
11 (19%) 
HNPCC, 3 (5%) 
FAP 
23% Dukes A, 
34% Dukes B, 
16% Dukes C, 
27% Dukes D 
39% proximal 
colon, 61% distal 
colon 
39% mucinous 
adenocarcinoma 
29% grade I, 
44% grade II, 
27% grade III 
59% (5-year OS), 
75 months (mean 
survival time) 
Minardi 
(1998) 
37 patients age 
≤ 40 years 
treated for CRC 
1976-1997; 
Louisiana State 
University 
35% white; 
65% black 
59% male, 
41% female 
30.5 (mean), 
range 11-40 
Abdominal pain 
(65%), weight loss 
(57%), rectal 
bleeding (49%), 
nausea and 
vomiting (35%), 
constipation (24%), 
narrow caliber 
stools 19%) 
1 (2.7%) family 
history (not 
defined) 
2.7% Dukes A, 
35% Dukes B, 
38% Dukes C, 
22% Dukes D (1 
patient had 
carcinoma in 
situ) 
21.6% cecum, 
2.7% right colon, 
13.5% hepatic 
flexure, 10.8% 
mid-transverse 
colon, 10.8% 
splenic flexure, 
10.8% left colon, 
16.2% sigmoid 
colon, 2.7% 
rectosigmoid 
junction, 10.8% 
rectum  
42% mucinous 
adenocarcinoma 
(3 had additional 
signet ring cell 
features); 58% 
typical 
adenocarcinoma 
15% well-
differentiated, 
38% moderately 
differentiated, 
46% poorly 
differentiated 
26% (5-year OS) 
1
1
6
 
 
 
Author 
(year) 
Study 
Population 
Race Sex Age 
Symptoms at 
Diagnosis 
Family History 
Stage at 
Diagnosis 
Tumor Site Histology Tumor Grade Overall Survival 
Palmer 
(1991) 
105 patients 
age ≤ 39 years 
treated for CRC 
1973-1985; 
Roswell Park 
Cancer Institute 
 
49% male, 
51% female 
32 (mean), 
34 (median), 
range 14-39 
 4 (3.8%) FAP 
0.9% Dukes A, 
18.1% Dukes B, 
50% Dukes C, 
33% Dukes D  
   
42 months (mean 
survival time) 
Yilmazlar 
(1995) 
46 patients age 
≤ 40 years 
underwent 
CRC surgery 
1986-1993; no 
history FAP or 
HPNCC; 
Turkey 
  
50% male, 
50% female 
33 (mean), 
range 16-40 
Rectal bleeding 
(78%), abdominal 
pain (28%), weight 
loss (26%), change 
in bowel habits 
(22%), vomiting 
(7%) 
6 (13%) family 
history (not 
defined) 
4.3% stage I, 
19.6% stage II, 
43.5% stage III, 
32.6% stage IV 
69% rectum, 11% 
sigmoid colon, 9% 
left colon, 11% 
right colon 
28% mucinous 
adenocarcinoma 
15% well-
differentiated, 
37% moderately 
differentiated, 
20% poorly 
differentiated 
43.5% (5-year 
OS); 21.4 months 
(median survival 
time) 
Abbreviations: CRC, colorectal cancer; FAP, familial adenomatous polyposis; HNPCC, hereditary non-polyposis colorectal cancer; UC, ulcerative colitis; IBD, irritable bowel syndrome; CEA, carcinoembryonic 
antigen           
1Results reported stratified by sex in Fancher (2011) but summarized across sex in table         
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